GOName,GOID,DiseaseName,DiseaseID,InferenceChemicalQty,InferenceChemicalNames,InferenceGeneQty,InferenceGeneSymbols
2-oxoglutarate metabolic process,GO:0006103,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,GPT
4-hydroxyproline biosynthetic process,GO:0019472,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Fructose|Genistein,0,
4-hydroxyproline catabolic process,GO:0019470,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH4A1
4-hydroxyproline metabolic process,GO:0019471,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Dietary Fats|puerarin|Resveratrol,0,
4-nitrophenol metabolic process,GO:0018960,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP2E1
5-methylcytosine biosynthetic process,GO:0046082,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
5S class rRNA transcription by RNA polymerase III,GO:0042791,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
9-cis-retinoic acid biosynthetic process,GO:0042904,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH1A1
9-cis-retinoic acid metabolic process,GO:0042905,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH1A1
acetaldehyde biosynthetic process,GO:0046186,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Diethylnitrosamine|Ethanol,0,
acetaldehyde catabolic process,GO:0046187,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
acetaldehyde metabolic process,GO:0006117,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,mancozeb|Maneb,1,ALDH2
acetate biosynthetic process,GO:0019413,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|perfluorooctanoic acid,0,
acetate metabolic process,GO:0006083,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cholesterol|Dietary Fats|geraniol,0,
acetylcholine biosynthetic process,GO:0008292,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|sodium arsenite,0,
acetylcholine catabolic process,GO:0006581,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ACE
acetylcholine catabolic process in synaptic cleft,GO:0001507,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ACE
acetylcholine metabolic process,GO:0008291,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Choline|sodium arsenite,0,
acetylcholine secretion,GO:0061526,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
acetyl-CoA biosynthetic process,GO:0006085,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Acetaminophen|cobaltiprotoporphyrin|Glucose|Streptozocin,0,
acetyl-CoA biosynthetic process from pyruvate,GO:0006086,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PDK4
acetyl-CoA metabolic process,GO:0006084,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium Chloride|Glucose,0,
acinar cell differentiation,GO:0090425,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NR5A2
acrosome reaction,GO:0007340,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|puerarin|Taurine,0,
actin cytoskeleton organization,GO:0030036,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|cyanoginosin LR|Genistein|Plant Extracts|Thioctic Acid,2,MRTFA|PTEN
actin cytoskeleton reorganization,GO:0031532,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|hydroquinone,0,
actin filament bundle assembly,GO:0051017,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Triclosan,0,
actin filament capping,GO:0051693,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RDX
actin filament depolymerization,GO:0030042,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Cadmium Chloride,0,
actin filament polymerization,GO:0030041,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,cyanoginosin LR|Ethanol|Resveratrol|Tetrachlorodibenzodioxin,1,JAK2
action potential initiation,GO:0099610,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Valproic Acid,0,
activated T cell proliferation,GO:0050798,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL4
activation-induced cell death of T cells,GO:0006924,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
activation of adenylate cyclase activity,GO:0007190,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
activation of cysteine-type endopeptidase activity,GO:0097202,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Cadmium Chloride|Folic Acid|Glucose|Reactive Oxygen Species|Resveratrol,0,
activation of cysteine-type endopeptidase activity involved in apoptotic process,GO:0006919,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,"Arsenic Trioxide|Benzo(a)pyrene|Cadmium|Resveratrol|theaflavin-3,3'-digallate|tributyltin",0,
activation of GTPase activity,GO:0090630,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|tributyltin,0,
activation of immune response,GO:0002253,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
activation of Janus kinase activity,GO:0042976,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,IL3|IL4|JAK2
activation of phospholipase C activity,GO:0007202,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
activation of protein kinase A activity,GO:0034199,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Quercetin|Resveratrol,0,
activation of protein kinase activity,GO:0032147,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"5-(3-methoxy-5-(4-methoxystyryl)phenoxy)-2,2-dimethylpentanoic acid|acanthoic acid|Ethanol",1,PRKCD
activation of protein kinase B activity,GO:0032148,Non-alcoholic Fatty Liver Disease,MESH:D065626,41,"4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid|Allopurinol|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Blood Glucose|Cadmium Chloride|Cholesterol|Cholesterol, Dietary|Choline|cobaltiprotoporphyrin|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Fats|Diethylnitrosamine|Ethanol|Folic Acid|Fructose|Genistein|geraniol|Glucose|hydroquinone|Methionine|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Orlistat|Palmitates|Palmitic Acid|Plant Extracts|puerarin|Quercetin|Reactive Oxygen Species|Resveratrol|sodium arsenite|Streptozocin|Sulpiride|Tamoxifen|Testosterone|Tobacco Smoke Pollution|tributyltin|Triclosan",1,INS
activation of protein kinase C activity,GO:1990051,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|geraniol|Glucose|Quercetin|Reactive Oxygen Species|tributyltin,1,LEP
acute inflammatory response,GO:0002526,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"Arsenic Trioxide|Cholesterol, Dietary|Dextran Sulfate|Dietary Fats",2,EIF2AK1|NLRP3
acute-phase response,GO:0006953,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,geraniol,4,F2|IL1RN|INS|SERPINA1
acyl-CoA metabolic process,GO:0006637,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
acylglycerol acyl-chain remodeling,GO:0036155,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PNPLA3
acylglycerol homeostasis,GO:0055090,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
acylglycerol metabolic process,GO:0006639,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Acetaminophen|bisphenol A,0,
adaptive immune response,GO:0002250,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,perfluorooctanoic acid|Tetrachlorodibenzodioxin,1,JAK2
adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,GO:0002460,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
adaptive thermogenesis,GO:1990845,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Caffeine,0,
adenine metabolic process,GO:0046083,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Cadmium Chloride|perfluorooctanoic acid,0,
adenosine biosynthetic process,GO:0046086,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,sodium arsenite|Streptozocin,0,
adenosine catabolic process,GO:0006154,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Fructose,0,
adenosine metabolic process,GO:0046085,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Dextran Sulfate|perfluorooctanoic acid|S-Adenosylhomocysteine|sodium arsenite,0,
adenylate cyclase-activating G protein-coupled receptor signaling pathway,GO:0007189,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,1,PRKACA
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway,GO:0007193,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,1,PRKACA
adhesion of symbiont to host,GO:0044406,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SCARB1
adiponectin-activated signaling pathway,GO:0033211,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ADIPOQ
adiponectin secretion,GO:0070162,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"Cholesterol, Dietary|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|Plant Preparations",0,
adipose tissue development,GO:0060612,Non-alcoholic Fatty Liver Disease,MESH:D065626,23,Benzo(a)pyrene|Bezafibrate|bisphenol A|Cadmium|Cadmium Chloride|Dietary Carbohydrates|Dietary Fats|flavangenol|Folic Acid|Genistein|Niacin|Olanzapine|perfluorohexanesulfonic acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Quercetin|Resveratrol|Rosiglitazone|sodium arsenite|Sodium Glutamate|Testosterone|tributyltin,4,FTO|LEP|PPARD|XBP1
ADP biosynthetic process,GO:0006172,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dextran Sulfate|Tobacco Smoke Pollution,0,
ADP metabolic process,GO:0046031,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium Chloride|perfluorooctanoic acid|Quercetin,0,
adrenal gland development,GO:0030325,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,1,CYP17A1
adult behavior,GO:0030534,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|gastrodin",1,PTEN
adult fat body development,GO:0007505,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
adult feeding behavior,GO:0008343,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,"3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|Dietary Carbohydrates|Dietary Fats|Ethanol|Fructose",1,LEP
adult locomotory behavior,GO:0008344,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,"Acetaminophen|Benzo(a)pyrene|bisphenol A|Ethanol|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|perfluoro-n-nonanoic acid|sodium arsenite|Streptozocin|Taurine|Valproic Acid",0,
adult walking behavior,GO:0007628,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Copper|Ethanol,0,
aerobic electron transport chain,GO:0019646,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,geraniol|Streptozocin|Tetrachlorodibenzodioxin,0,
aerobic respiration,GO:0009060,Non-alcoholic Fatty Liver Disease,MESH:D065626,18,Acetaminophen|Benzo(a)pyrene|Bile Acids and Salts|bisphenol A|Cadmium|Cadmium Chloride|cyanoginosin LR|Dietary Fats|Glucose|Maneb|Oleic Acid|Quercetin|Resveratrol|Rosiglitazone|sodium arsenite|Testosterone|tributyltin|Valproic Acid,1,CAT
aflatoxin catabolic process,GO:0046223,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NFE2L2
aflatoxin metabolic process,GO:0046222,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,AHR|CPT1A|CYP1A2|SCARB1
aggressive behavior,GO:0002118,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|perfluoro-n-nonanoic acid,0,
aging,GO:0007568,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"theaflavin-3,3'-digallate",0,
agmatine biosynthetic process,GO:0097055,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
alanine biosynthetic process,GO:0006523,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|tributyltin,0,
alanine metabolic process,GO:0006522,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Cadmium Chloride|Tobacco Smoke Pollution,0,
alcohol catabolic process,GO:0046164,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ADH4
alcohol metabolic process,GO:0006066,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,ADH1A|ADH4|ALDH2
aldehyde catabolic process,GO:0046185,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH2
aldosterone biosynthetic process,GO:0032342,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
aldosterone metabolic process,GO:0032341,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
aldosterone secretion,GO:0035932,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,0,
alkaloid metabolic process,GO:0009820,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,1,CYP1A2
allantois development,GO:1905069,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Caffeine,0,
alpha-beta T cell activation,GO:0046631,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,INS
alpha-linolenic acid metabolic process,GO:0036109,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|sodium arsenite,0,
alpha-tubulin acetylation,GO:0071929,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,"Cadmium Chloride|Niacin|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Resveratrol",0,
amide metabolic process,GO:0043603,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Acetaminophen|Ethanol,0,
amine metabolic process,GO:0009308,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Choline|Dextran Sulfate,0,
amino-acid betaine biosynthetic process,GO:0006578,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
amino-acid betaine metabolic process,GO:0006577,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Ethanol,0,
amino acid biosynthetic process,GO:0008652,Non-alcoholic Fatty Liver Disease,MESH:D065626,12,Acetaminophen|bisphenol A|Cadmium|Dextran Sulfate|Dietary Fats|Ethanol|Folic Acid|Methionine|Olive Oil|perfluorooctanoic acid|S-Adenosylhomocysteine|Valproic Acid,0,
amino acid metabolic process,GO:0006520,Non-alcoholic Fatty Liver Disease,MESH:D065626,14,Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Dextran Sulfate|Ethanol|Methionine|Resveratrol|S-Adenosylhomocysteine|S-Adenosylmethionine|sodium arsenite|Streptozocin|Taurine|Tetrachlorodibenzodioxin,0,
amino acid transport,GO:0006865,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Choline,0,
ammonium excretion,GO:0140734,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
ammonium homeostasis,GO:0097272,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Acetaminophen|bisphenol A|Tetrachlorodibenzodioxin,0,
AMP catabolic process,GO:0006196,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Caffeine,0,
AMP metabolic process,GO:0046033,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Dietary Fats|Ethanol|Folic Acid|perfluorooctanoic acid,0,
amyloid-beta clearance,GO:0097242,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LDLR
amyloid-beta clearance by cellular catabolic process,GO:0150094,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LDLR
amyloid-beta metabolic process,GO:0050435,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"Cholesterol, Dietary",1,ACE
amyloid fibril formation,GO:1990000,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Raloxifene Hydrochloride,0,
anagen,GO:0042640,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PPARD
anatomical structure development,GO:0048856,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Valproic Acid,0,
anatomical structure regression,GO:0060033,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|sodium arsenite,0,
androgen biosynthetic process,GO:0006702,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Cholesterol|perfluorooctanoic acid|Testosterone,2,CYP17A1|SCARB1
androgen catabolic process,GO:0006710,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Testosterone,0,
androgen metabolic process,GO:0008209,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Quercetin|sodium arsenite|Testosterone,1,ESR1
androgen receptor signaling pathway,GO:0030521,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Resveratrol|Testosterone,0,
"androst-4-ene-3,17-dione biosynthetic process",GO:1903449,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP17A1
androstenedione secretion,GO:0035941,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Sodium Glutamate,0,
angioblast cell migration,GO:0035476,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
angiogenesis,GO:0001525,Non-alcoholic Fatty Liver Disease,MESH:D065626,13,Acetaminophen|Arsenic Trioxide|bisphenol A|Cadmium|Caffeine|Copper|cyanoginosin LR|Diethylnitrosamine|Ethanol|Folic Acid|Glucose|Quercetin|Streptozocin,6,ATP5F1B|LEP|PRKCA|PTEN|SIRT1|XBP1
angiogenesis involved in coronary vascular morphogenesis,GO:0060978,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ACE
angiotensin-activated signaling pathway,GO:0038166,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,1,ACE
angiotensin maturation,GO:0002003,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ACE
animal organ development,GO:0048513,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluoro-n-nonanoic acid,0,
animal organ morphogenesis,GO:0009887,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,FGF21|LAMA1|TGFB1|TNF
animal organ regeneration,GO:0031100,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,6,ACE|APOH|GSTP1|LIF|PPARG|TGFB1
anisotropic cell growth,GO:0051211,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
anoikis,GO:0043276,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IKBKG
anterior neuropore closure,GO:0021506,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
antibiotic metabolic process,GO:0016999,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ABCC2
antigen processing and presentation of exogenous peptide antigen via MHC class I,GO:0042590,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IFI30
antigen processing and presentation of exogenous peptide antigen via MHC class II,GO:0019886,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IFI30
antigen processing and presentation of peptide antigen via MHC class I,GO:0002474,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ACE
antimicrobial humoral immune response mediated by antimicrobial peptide,GO:0061844,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,F2
antimicrobial humoral response,GO:0019730,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
antiviral innate immune response,GO:0140374,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNF
antral ovarian follicle growth,GO:0001547,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,Acetaminophen|alpha-naphthoflavone|bisphenol A|Genistein|perfluorooctanoic acid|Resveratrol|sodium arsenite|Taurine|tributyltin,1,ESR1
aorta development,GO:0035904,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LEP
aorta morphogenesis,GO:0035909,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
aortic valve development,GO:0003176,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNFRSF1B
aortic valve morphogenesis,GO:0003180,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
apical protein localization,GO:0045176,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Valproic Acid,1,RDX
apoptotic chromosome condensation,GO:0030263,Non-alcoholic Fatty Liver Disease,MESH:D065626,24,"Acetaminophen|Arsenic Trioxide|bisphenol A|Blood Glucose|bromodichloromethane|Cadmium|Cadmium Chloride|cyanoginosin LR|Dietary Fats|Ethanol|Fenofibrate|Genistein|Maneb|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Plant Extracts|Quercetin|Resveratrol|sodium arsenite|Sodium Glutamate|Streptozocin|Taurine|Thioctic Acid|tributyltin|Valproic Acid",0,
apoptotic DNA fragmentation,GO:0006309,Non-alcoholic Fatty Liver Disease,MESH:D065626,32,Acetaminophen|aroclor 1260|Arsenic Trioxide|Cadmium|Cadmium Chloride|Caffeine|Carvedilol|cyanoginosin LR|Dietary Fats|Ethanol|Genistein|Glucocorticoids|Glucose|Irinotecan|Methionine|perfluorooctanoic acid|Plant Extracts|Prednisolone|Quercetin|Raloxifene Hydrochloride|Reactive Oxygen Species|Resveratrol|Rosiglitazone|S-Adenosylmethionine|sodium arsenite|Streptozocin|Taurine|Testosterone|Tetrachlorodibenzodioxin|tributyltin|Tunicamycin|Valproic Acid,0,
apoptotic mitochondrial changes,GO:0008637,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH2
apoptotic nuclear changes,GO:0030262,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,Arsenic Trioxide|bisphenol A|Ethanol|Maneb|Plant Extracts|sodium arsenite|Testosterone|Thioctic Acid|Tobacco Smoke Pollution,0,
apoptotic process,GO:0006915,Non-alcoholic Fatty Liver Disease,MESH:D065626,80,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|4-hydroxy-2-nonenal|Acetaminophen|Allopurinol|alpha-naphthoflavone|Arsenic Trioxide|Benzo(a)pyrene|Bezafibrate|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Carvedilol|Cholesterol|Cholesterol, Dietary|Choline|Chromium|cobaltiprotoporphyrin|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Fats|Dietary Sucrose|Diethylnitrosamine|Dimethylnitrosamine|Ethanol|Fenofibrate|Folic Acid|Fructose|gastrodin|Genistein|Glucocorticoids|Glucose|Hydralazine|hydroquinone|Irinotecan|Iron|mancozeb|Maneb|Methionine|Niacin|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|obeticholic acid|Olanzapine|Oleic Acid|Orlistat|Orotic Acid|Palmitates|Palmitic Acid|perfluorooctanoic acid|Phenylbutyrates|Pioglitazone|pirinixic acid|Plant Extracts|Plant Preparations|Prednisolone|puerarin|Quercetin|Raloxifene Hydrochloride|Reactive Oxygen Species|Resveratrol|Rosiglitazone|S-Adenosylmethionine|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Sucrose|Tamoxifen|Taurine|Testosterone|Tetrachlorodibenzodioxin|theaflavin-3,3'-digallate|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Triclosan|Tunicamycin|Valproic Acid",16,AHR|ALDH1A1|CD14|FAS|IKBKG|IL1A|IL1B|JAK2|NLRP3|PPARD|PRF1|PRKCA|PRKCD|PRKCE|PTEN|TNFRSF1B
apoptotic signaling pathway,GO:0097190,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,FAS|PPARD|PRKCA|TNF
arabinose biosynthetic process,GO:0019567,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
arachidonic acid metabolic process,GO:0019369,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,bisphenol A|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Resveratrol|Rosiglitazone|sodium arsenite|Tetrachlorodibenzodioxin,1,CYP1A2
arachidonic acid secretion,GO:0050482,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ACE
arginine biosynthetic process,GO:0006526,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|Irinotecan,0,
arginine metabolic process,GO:0006525,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
arsenite transport,GO:0015700,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|sodium arsenite,0,
artery development,GO:0060840,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LDLR
artery morphogenesis,GO:0048844,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LDLR
artery smooth muscle contraction,GO:0014824,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Dietary Carbohydrates|Plant Preparations|Resveratrol|sodium arsenite|Tobacco Smoke Pollution,0,
articular cartilage development,GO:0061975,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
asparagine biosynthetic process,GO:0006529,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Acetaminophen,0,
aspartate biosynthetic process,GO:0006532,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Acetaminophen,0,
aspartate catabolic process,GO:0006533,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Dimethylnitrosamine|Plant Extracts|puerarin,0,
aspartate metabolic process,GO:0006531,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
associative learning,GO:0008306,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Benzo(a)pyrene|bisphenol A,0,
astral microtubule nucleation,GO:0030954,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
astrocyte activation,GO:0048143,Non-alcoholic Fatty Liver Disease,MESH:D065626,11,bisphenol A|Blood Glucose|Cadmium Chloride|Dietary Fats|Quercetin|Reactive Oxygen Species|Resveratrol|sodium arsenite|Sodium Glutamate|Streptozocin|tributyltin,2,IL1B|TNF
astrocyte activation involved in immune response,GO:0002265,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
astrocyte cell migration,GO:0043615,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
astrocyte development,GO:0014002,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|Cadmium|Ethanol|Plant Extracts|Quercetin|sodium arsenite,0,
astrocyte differentiation,GO:0048708,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,1,LIF
ATF6-mediated unfolded protein response,GO:0036500,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,XBP1
ATP biosynthetic process,GO:0006754,Non-alcoholic Fatty Liver Disease,MESH:D065626,29,"Acetaminophen|alpha-naphthoflavone|Arsenic Trioxide|Benzo(a)pyrene|Bile Acids and Salts|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Copper|cyanoginosin LR|Dietary Fats|Ethanol|Fenofibrate|Glucose|Irinotecan|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Plant Extracts|puerarin|Quercetin|Resveratrol|Rosiglitazone|sodium arsenite|Streptozocin|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Valproic Acid",2,ATP5F1B|TGFB1
ATP generation from ADP,GO:0006757,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
ATP metabolic process,GO:0046034,Non-alcoholic Fatty Liver Disease,MESH:D065626,36,"4-hydroxy-2-nonenal|Acetaminophen|Allopurinol|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Blood Glucose|Cadmium|Cadmium Chloride|carnosol|Dietary Fats|Ethanol|geraniol|Glucose|hydroquinone|Niacin|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|obeticholic acid|Orotic Acid|osteum|Palmitic Acid|perfluorooctanoic acid|Plant Extracts|puerarin|Quercetin|Raloxifene Hydrochloride|Resveratrol|Rosiglitazone|Silymarin|sodium arsenite|Streptozocin|Taurine|Triclosan|Tunicamycin|Valproic Acid",1,ATP5F1B
attachment of mitotic spindle microtubules to kinetochore,GO:0051315,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
attachment of spindle microtubules to kinetochore,GO:0008608,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
auditory behavior,GO:0031223,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Cadmium Chloride|Dietary Fats,0,
autophagic cell death,GO:0048102,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Resveratrol,0,
autophagosome assembly,GO:0000045,Non-alcoholic Fatty Liver Disease,MESH:D065626,14,4-hydroxy-2-nonenal|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Ethanol|Glucose|Quercetin|Raloxifene Hydrochloride|Resveratrol|sodium arsenite|Tunicamycin,0,
autophagosome-lysosome fusion,GO:0061909,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Arsenic Trioxide|Cadmium|Cadmium Chloride|Cholesterol|Palmitic Acid|sodium arsenite,0,
autophagosome maturation,GO:0097352,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Glucose|sodium arsenite,0,
autophagosome organization,GO:1905037,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Arsenic Trioxide|Cadmium|Cadmium Chloride|Palmitic Acid|Resveratrol,0,
autophagy,GO:0006914,Non-alcoholic Fatty Liver Disease,MESH:D065626,28,Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Cholesterol|Copper|cyanoginosin LR|Dietary Fats|Ethanol|Glucose|hydroquinone|Iron|Oleic Acid|Orlistat|Palmitic Acid|Quercetin|Raloxifene Hydrochloride|Reactive Oxygen Species|Resveratrol|Rosiglitazone|sodium arsenite|Streptozocin|Tamoxifen|Taurine|Thioctic Acid|Tunicamycin,3,IL4|PTEN|XBP1
autophagy of mitochondrion,GO:0000422,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Acetaminophen|Cadmium|Cadmium Chloride,0,
axo-dendritic transport,GO:0008088,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Streptozocin,0,
axon development,GO:0061564,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Benzo(a)pyrene|Cadmium Chloride|sodium arsenite,0,
axon ensheathment,GO:0008366,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PPARD
axon extension,GO:0048675,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|gastrodin|Thioctic Acid,0,
axon guidance,GO:0007411,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Copper,1,LAMA1
axonogenesis,GO:0007409,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Sodium Glutamate,1,LAMA1
axon regeneration,GO:0031103,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
B-1 B cell homeostasis,GO:0001922,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR
baculum development,GO:1990375,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,1,ESR1
barbed-end actin filament capping,GO:0051016,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RDX
base-excision repair,GO:0006284,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|sodium arsenite",0,
basement membrane disassembly,GO:0034769,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
basement membrane organization,GO:0071711,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,sodium arsenite|Streptozocin,2,MMP1|PTEN
B cell activation,GO:0042113,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,IL4|TNFRSF1B
B cell apoptotic process,GO:0001783,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL3
B cell costimulation,GO:0031296,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL4
B cell differentiation,GO:0030183,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Tetrachlorodibenzodioxin|tributyltin,3,AHR|IL4|RAG2
B cell homeostasis,GO:0001782,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,2,AHR|IKBKG
B cell homeostatic proliferation,GO:0002358,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RAG2
B cell lineage commitment,GO:0002326,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Cadmium Chloride|Tetrachlorodibenzodioxin,1,RAG2
B cell mediated immunity,GO:0019724,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
B cell proliferation,GO:0042100,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,perfluorooctanoic acid|Plant Extracts|Resveratrol,4,IL3|IL4|PRKCD|PTEN
behavior,GO:0007610,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|Cadmium|Coal|Dietary Fats|perfluorooctanoic acid|Tobacco Smoke Pollution,0,
behavioral defense response,GO:0002209,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Ethanol,0,
behavioral fear response,GO:0001662,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,"bisphenol A|Cadmium|Cadmium Chloride|Ethanol|Folic Acid|Maneb|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Taurine",0,
behavioral response to acetic acid induced pain,GO:0061367,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Acetaminophen|geraniol|Plant Extracts,0,
behavioral response to chemical pain,GO:0061366,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Linoleic Acid|Plant Extracts|Resveratrol,0,
behavioral response to ethanol,GO:0048149,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,2,ALDH2|SIRT1
behavioral response to formalin induced pain,GO:0061368,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,geraniol|Plant Extracts|Silymarin|sodium arsenite,0,
behavioral response to nicotine,GO:0035095,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PPARA
behavioral response to pain,GO:0048266,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,Acetaminophen|cobaltiprotoporphyrin|Glucose|Plant Extracts|sodium arsenite|Streptozocin|Testosterone|Valproic Acid,0,
behavioral response to starvation,GO:0042595,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SIRT1
behavioral response to water deprivation,GO:0042630,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
benzene metabolic process,GO:0018910,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP2E1
benzoate transport,GO:0042919,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Niacin|Valproic Acid,0,
benzylpenicillin metabolic process,GO:1901086,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ABCC2
bicarbonate transport,GO:0015701,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
bile acid and bile salt transport,GO:0015721,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Bile Acids and Salts|Dietary Fats|perfluoro-n-nonanoic acid|tectorigenin,2,ABCC2|NR1H4
bile acid biosynthetic process,GO:0006699,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,"bisphenol A|Cholesterol, Dietary|Dietary Fats|Ethanol|perfluorohexanesulfonic acid|perfluorooctanoic acid",0,
bile acid conjugation,GO:0002152,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Streptozocin,0,
bile acid metabolic process,GO:0008206,Non-alcoholic Fatty Liver Disease,MESH:D065626,16,Acetaminophen|Arsenic Trioxide|Benzo(a)pyrene|Bile Acids and Salts|bisphenol A|Cadmium|Chromium|Copper|Dietary Fats|Ethanol|GW 4064|obeticholic acid|perfluorooctanoic acid|Taurine|tectorigenin|Tetrachlorodibenzodioxin,3,LEP|NR1H4|NR5A2
bile acid secretion,GO:0032782,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,obeticholic acid|perfluoro-n-nonanoic acid|Resveratrol|Tetrachlorodibenzodioxin,1,ABCB4
bile acid signaling pathway,GO:0038183,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NR1H4
bilirubin transport,GO:0015723,Non-alcoholic Fatty Liver Disease,MESH:D065626,15,"Acetaminophen|Cholates|Cholesterol, Dietary|cocoa butter|Dietary Fats|Folic Acid|geraniol|obeticholic acid|Plant Extracts|Prednisolone|puerarin|Resveratrol|Rosiglitazone|Silymarin|Taurine",1,ABCC2
binding of sperm to zona pellucida,GO:0007339,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
biological_process,GO:0008150,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,ALDH1B1|C1QC|LAMA1
biological process involved in interaction with host,GO:0051701,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,cobaltiprotoporphyrin,0,
biological process involved in symbiotic interaction,GO:0044403,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Dietary Fats|Dietary Sugars|Streptozocin,0,
biomineral tissue development,GO:0031214,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
biosynthetic process,GO:0009058,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,GPT
biphenyl metabolic process,GO:0018879,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP17A1
blastocyst development,GO:0001824,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Genistein|perfluorohexanesulfonic acid,0,
blastocyst formation,GO:0001825,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|bisphenol A|Resveratrol|Tetrachlorodibenzodioxin|Triclosan,0,
blastocyst growth,GO:0001832,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
blastocyst hatching,GO:0001835,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,1,PEMT
bleb assembly,GO:0032060,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|sodium arsenite,0,
blood circulation,GO:0008015,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Dextran Sulfate|Genistein|Irinotecan,1,AHR
blood coagulation,GO:0007596,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Genistein|Irinotecan|Plant Extracts,2,F2|SERPINA1
"blood coagulation, fibrin clot formation",GO:0072378,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Acetaminophen|Copper,0,
"blood coagulation, intrinsic pathway",GO:0007597,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,APOH
blood vessel development,GO:0001568,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Glucose|Quercetin|Resveratrol,2,AHR|LAMA1
blood vessel diameter maintenance,GO:0097746,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Cadmium|Resveratrol|Tobacco Smoke Pollution,1,ACE
blood vessel endothelial cell migration,GO:0043534,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SCARB1
blood vessel morphogenesis,GO:0048514,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,AHR|LAMA1
blood vessel remodeling,GO:0001974,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Tobacco Smoke Pollution,3,ACE|AHR|LIF
BMP signaling pathway,GO:0030509,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,PPARG|TGFB1
body morphogenesis,GO:0010171,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Benzo(a)pyrene|sodium arsenite,0,
bone development,GO:0060348,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Ethanol|Prednisolone,0,
bone growth,GO:0098868,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,"Acetaminophen|aroclor 1260|bisphenol A|Cadmium|Caffeine|theaflavin-3,3'-digallate",1,LEP
bone marrow development,GO:0048539,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tetrachlorodibenzodioxin,0,
bone mineralization,GO:0030282,Non-alcoholic Fatty Liver Disease,MESH:D065626,18,"Allopurinol|Benzo(a)pyrene|bisphenol A|Cadmium|Dietary Fats|Ethanol|Glucose|Niacin|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Prednisolone|Quercetin|Raloxifene Hydrochloride|Streptozocin|Tamoxifen|Tetrachlorodibenzodioxin|theaflavin-3,3'-digallate",0,
bone mineralization involved in bone maturation,GO:0035630,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LEP
bone morphogenesis,GO:0060349,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"3,4,5,3',4'-pentachlorobiphenyl",0,
bone remodeling,GO:0046849,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"3,4,5,3',4'-pentachlorobiphenyl|Arsenic Trioxide|Cadmium|Ethanol",0,
bone resorption,GO:0045453,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Cadmium|Cadmium Chloride|Iron|Raloxifene Hydrochloride|sodium arsenite,0,
bone trabecula formation,GO:0060346,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Benzo(a)pyrene|Dietary Fats|Streptozocin,0,
bradykinin catabolic process,GO:0010815,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ACE
brain-derived neurotrophic factor receptor signaling pathway,GO:0031547,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Plant Extracts,0,
brain development,GO:0007420,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Ethanol|Folic Acid|Quercetin|Tobacco Smoke Pollution|Triclosan,1,LAMA1
brain morphogenesis,GO:0048854,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Ethanol,2,LAMA1|PTEN
branched-chain amino acid metabolic process,GO:0009081,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Niacin|Triclosan,0,
branch elongation involved in mammary gland duct branching,GO:0060751,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
branching involved in blood vessel morphogenesis,GO:0001569,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR
branching involved in mammary gland duct morphogenesis,GO:0060444,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Cadmium|Cadmium Chloride|Genistein|Tetrachlorodibenzodioxin,0,
branching involved in salivary gland morphogenesis,GO:0060445,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LAMA1
bronchiole development,GO:0060435,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
brown fat cell differentiation,GO:0050873,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Resveratrol|Rosiglitazone|tributyltin,2,ADIPOQ|PPARG
brown fat cell proliferation,GO:0070342,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Sodium Glutamate|Taurine|tributyltin,0,
brush border assembly,GO:1904970,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,geraniol,0,
butyrate metabolic process,GO:0019605,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
C21-steroid hormone biosynthetic process,GO:0006700,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Caffeine|Ethanol,0,
C21-steroid hormone metabolic process,GO:0008207,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cholesterol|Testosterone,0,
C-5 methylation of cytosine,GO:0090116,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,Benzo(a)pyrene|bisphenol A|Cadmium Chloride|perfluorooctanoic acid|Resveratrol|S-Adenosylmethionine|sodium arsenite|Tobacco Smoke Pollution,0,
cadmium ion homeostasis,GO:0055073,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
cadmium ion transport,GO:0015691,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Taurine,0,
calcineurin-mediated signaling,GO:0097720,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NR5A2
calcitriol biosynthetic process from calciol,GO:0036378,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tetrachlorodibenzodioxin,0,
calcium import into the mitochondrion,GO:0036444,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Valproic Acid,0,
calcium ion export,GO:1901660,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
calcium ion homeostasis,GO:0055074,Non-alcoholic Fatty Liver Disease,MESH:D065626,18,Acetaminophen|Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Dietary Fats|Dietary Sugars|Ethanol|Fructose|Glucose|perfluorooctanoic acid|Quercetin|Resveratrol|sodium arsenite|Streptozocin|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution|Valproic Acid,1,STC2
calcium ion import,GO:0070509,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|Benzo(a)pyrene|bisphenol A|Cadmium Chloride|Cholesterol|Glucose|Linoleic Acid|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Quercetin",0,
calcium ion import across plasma membrane,GO:0098703,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|Copper,1,MMP1
calcium ion import into cytosol,GO:1902656,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,alpha-naphthoflavone,0,
calcium ion transmembrane transport via high voltage-gated calcium channel,GO:0061577,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Arsenic Trioxide|Glucose|Resveratrol,0,
calcium ion transport,GO:0006816,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Glucose|Quercetin,0,
calcium ion transport from cytosol to endoplasmic reticulum,GO:1903515,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
calcium ion transport into cytosol,GO:0060402,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
calcium-mediated signaling,GO:0019722,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,Cadmium|Cadmium Chloride|Caffeine|Carvedilol|Glucose|Niacin|Resveratrol|Tamoxifen|Testosterone|Tetrachlorodibenzodioxin,1,TNF
calcium-mediated signaling using intracellular calcium source,GO:0035584,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,cyanoginosin LR|Glucose|tributyltin,0,
calmodulin dependent kinase signaling pathway,GO:0099004,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium Chloride,0,
camera-type eye development,GO:0043010,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,AHR|LAMA1
camera-type eye morphogenesis,GO:0048593,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LAMA1
cAMP biosynthetic process,GO:0006171,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,bisphenol A|Cadmium Chloride|Caffeine|Ethanol|perfluorooctanoic acid|Quercetin|Resveratrol|tributyltin,0,
cAMP-mediated signaling,GO:0019933,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,AHR|LEP
cAMP metabolic process,GO:0046058,Non-alcoholic Fatty Liver Disease,MESH:D065626,12,Arsenic Trioxide|Blood Glucose|Caffeine|Dietary Fats|Dietary Sugars|Ethanol|Maneb|Resveratrol|sodium arsenite|Streptozocin|Tamoxifen|Taurine,0,
canalicular bile acid transport,GO:0015722,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Bile Acids and Salts,1,ABCC2
cannabinoid biosynthetic process,GO:1901696,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Orlistat,0,
canonical glycolysis,GO:0061621,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Diethylnitrosamine|Maneb|sodium arsenite,0,
canonical Wnt signaling pathway,GO:0060070,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,PTEN|TGFB1
carbohydrate metabolic process,GO:0005975,Non-alcoholic Fatty Liver Disease,MESH:D065626,11,"3,4,5,3',4'-pentachlorobiphenyl|aroclor 1260|Benzo(a)pyrene|bisphenol A|Dextran Sulfate|Fructose|Genistein|Glucose|Palm Oil|sodium arsenite|Sucrose",4,ALDH1B1|ALDH2|B3GAT1|KLB
carbohydrate transport,GO:0008643,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
carbon tetrachloride metabolic process,GO:0018885,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP2E1
carboxylic acid metabolic process,GO:0019752,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Dextran Sulfate|perfluorooctanoic acid,1,IL1RN
cardiac atrium morphogenesis,GO:0003209,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tetrachlorodibenzodioxin,0,
cardiac chamber ballooning,GO:0003242,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
cardiac fibroblast cell differentiation,GO:0060935,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
cardiac left ventricle morphogenesis,GO:0003214,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR
cardiac muscle cell action potential,GO:0086001,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Streptozocin,0,
cardiac muscle cell apoptotic process,GO:0010659,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Glucose,1,SIRT1
cardiac muscle cell contraction,GO:0086003,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,bisphenol A|Caffeine|Ethanol|Palmitic Acid|Raloxifene Hydrochloride|Tamoxifen|Triclosan,0,
cardiac muscle cell development,GO:0055013,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|Tetrachlorodibenzodioxin,0,
cardiac muscle cell differentiation,GO:0055007,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Triclosan|Valproic Acid,1,MRTFA
cardiac muscle cell proliferation,GO:0060038,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
cardiac muscle contraction,GO:0060048,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Iron|Rosiglitazone|Streptozocin,0,
cardiac muscle hypertrophy,GO:0003300,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Ethanol|Plant Preparations|Resveratrol,1,LEP
cardiac muscle tissue development,GO:0048738,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
cardiac muscle tissue growth involved in heart morphogenesis,GO:0003245,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
cardiac muscle tissue morphogenesis,GO:0055008,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Tetrachlorodibenzodioxin,0,
cardiac ventricle morphogenesis,GO:0003208,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,"3,4,5,3',4'-pentachlorobiphenyl|Tetrachlorodibenzodioxin",0,
cardiolipin biosynthetic process,GO:0032049,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Tamoxifen|tributyltin,0,
carnitine biosynthetic process,GO:0045329,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Allopurinol|Arsenic Trioxide|Fructose|Olanzapine|perfluorooctanoic acid|Quercetin|sodium arsenite,0,
carnitine metabolic process,GO:0009437,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,bisphenol A|Choline|Fenofibrate|geraniol|Methionine|perfluorooctanoic acid|sodium arsenite,1,CPT1A
"carnitine metabolic process, CoA-linked",GO:0019254,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
carnitine shuttle,GO:0006853,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,1,CPT1A
carnitine transmembrane transport,GO:1902603,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Caffeine,0,
carnitine transport,GO:0015879,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Olanzapine,0,
cartilage development,GO:0051216,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|Ethanol|Valproic Acid",1,NR5A2
cartilage homeostasis,GO:1990079,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,0,
cartilage morphogenesis,GO:0060536,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
CD40 signaling pathway,GO:0023035,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNFRSF1B
"CD4-positive, alpha-beta T cell proliferation",GO:0035739,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,0,
"CD4-positive, CD25-positive, alpha-beta regulatory T cell lineage commitment",GO:0002362,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
CD80 biosynthetic process,GO:0035780,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Extracts,0,
CD86 biosynthetic process,GO:0035781,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Extracts,0,
"CD8-positive, alpha-beta cytotoxic T cell differentiation",GO:0002308,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
"CD8-positive, alpha-beta T cell activation",GO:0036037,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,S-Adenosylmethionine|Tetrachlorodibenzodioxin,0,
"CD8-positive, alpha-beta T cell proliferation",GO:0035740,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,0,
CDP metabolic process,GO:0046704,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
cell-abiotic substrate adhesion,GO:0036164,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,4-hydroxy-2-nonenal|bisphenol A|sodium arsenite|Tamoxifen,0,
cell activation,GO:0001775,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Maneb|Resveratrol|sodium arsenite,1,TGFB1
cell adhesion,GO:0007155,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,"3,4,5,3',4'-pentachlorobiphenyl|Arsenic Trioxide|bisphenol A|Folic Acid|Glucose|Plant Extracts|Resveratrol|sodium arsenite",8,F2|FOLR2|JAK2|LAMA1|MMP1|PRKCA|PRKCE|TM6SF2
cell aggregation,GO:0098743,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Benzo(a)pyrene|bisphenol A|Plant Extracts,0,
cell-cell adhesion,GO:0098609,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,"bisphenol A|Glucose|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Palmitates|perfluorooctanoic acid|Plant Extracts|sodium arsenite",0,
cell-cell adhesion in response to extracellular stimulus,GO:0140039,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Resveratrol,0,
cell-cell fusion,GO:0140253,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Valproic Acid,0,
cell-cell junction assembly,GO:0007043,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Thioctic Acid,1,NR1H4
cell-cell junction maintenance,GO:0045217,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium Chloride,0,
cell-cell junction organization,GO:0045216,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,2,MMP1|TGFB1
cell-cell signaling,GO:0007267,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Cadmium|Cadmium Chloride|Genistein|Resveratrol,4,FGF21|IL1B|IL3|INS
cell-cell signaling via exosome,GO:0099156,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Acetaminophen|sodium arsenite,0,
cell chemotaxis,GO:0060326,Non-alcoholic Fatty Liver Disease,MESH:D065626,19,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|cyanoginosin LR|Folic Acid|hydroquinone|perfluorooctanoic acid|Plant Extracts|Quercetin|Raloxifene Hydrochloride|Resveratrol|Rosiglitazone|sodium arsenite|Tamoxifen|Valproic Acid",1,PRKCD
cell communication,GO:0007154,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"3,4,5,3',4'-pentachlorobiphenyl|Cholesterol|Triglycerides",0,
cell communication by electrical coupling involved in cardiac conduction,GO:0086064,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRKACA
cell competition in a multicellular organism,GO:0035212,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
cell cycle,GO:0007049,Non-alcoholic Fatty Liver Disease,MESH:D065626,32,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|alpha-naphthoflavone|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Caffeine|Carvedilol|Cholesterol|Genistein|Glucose|Irinotecan|Linoleic Acid|Methionine|Niacin|Orlistat|Phenylbutyrates|Plant Extracts|Prednisolone|Raloxifene Hydrochloride|Reactive Oxygen Species|Resveratrol|Rosiglitazone|sodium arsenite|Streptozocin|Tamoxifen|Tetrachlorodibenzodioxin|Thioctic Acid|Tobacco Smoke Pollution|Toremifene|Valproic Acid",0,
cell cycle checkpoint signaling,GO:0000075,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
cell death,GO:0008219,Non-alcoholic Fatty Liver Disease,MESH:D065626,65,"4-hydroxy-2-nonenal|Acetaminophen|Allopurinol|alpha-naphthoflavone|Arsenic Trioxide|Benzo(a)pyrene|Bezafibrate|bisphenol A|Blood Glucose|Cadmium|Cadmium Chloride|Caffeine|Carvedilol|Cholesterol|cobaltiprotoporphyrin|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Fats|Dust|Ethanol|Eucalyptol|Fenofibrate|Folic Acid|gastrodin|Genistein|Glucocorticoids|Glucose|GW 501516|Hydralazine|hydroquinone|Irinotecan|Iron|Linoleic Acid|mancozeb|Maneb|Methionine|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Oleic Acid|Orlistat|Palmitates|Palmitic Acid|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|pirinixic acid|Plant Extracts|Quercetin|Raloxifene Hydrochloride|Reactive Oxygen Species|Resveratrol|Rosiglitazone|sodium arsenite|Sodium Glutamate|Streptozocin|Tamoxifen|Taurine|Testosterone|Tetrachlorodibenzodioxin|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Triclosan|Tunicamycin|Valproic Acid",0,
cell death in response to hydrogen peroxide,GO:0036474,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Genistein|Resveratrol,0,
cell development,GO:0048468,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Triclosan,0,
cell differentiation,GO:0030154,Non-alcoholic Fatty Liver Disease,MESH:D065626,20,Arsenic Trioxide|bisphenol A|Caffeine|Dabigatran|Ethanol|Genistein|Glucocorticoids|Glucose|hydroquinone|Phenylbutyrates|Plant Extracts|Quercetin|Reactive Oxygen Species|Resveratrol|Rosiglitazone|sodium arsenite|Testosterone|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution|Valproic Acid,6,FGF21|JAK2|NR1H4|PPARA|PPARD|PPARG
cell division,GO:0051301,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,1,PRKCE
cell fate commitment,GO:0045165,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,1,PPARG
cell growth,GO:0016049,Non-alcoholic Fatty Liver Disease,MESH:D065626,39,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|3,4,5,3',4'-pentachlorobiphenyl|4-hydroxy-2-nonenal|Acetaminophen|Allopurinol|alpha-naphthoflavone|Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Dietary Fats|Diethylnitrosamine|Ethanol|Folic Acid|Glucose|hydroquinone|Maneb|Methionine|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Palmitates|Palmitic Acid|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Plant Extracts|Plant Preparations|Quercetin|Raloxifene Hydrochloride|Resveratrol|sodium arsenite|Sucrose|Tamoxifen|Tetrachlorodibenzodioxin|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Triclosan|Valproic Acid",0,
cell growth involved in cardiac muscle cell development,GO:0061049,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Rosiglitazone,0,
cell killing,GO:0001906,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Irinotecan,0,
cell-matrix adhesion,GO:0007160,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LDLR
cell maturation,GO:0048469,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"Cadmium Chloride|Ethanol|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride",1,PPARG
cell migration,GO:0016477,Non-alcoholic Fatty Liver Disease,MESH:D065626,28,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|alpha-naphthoflavone|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Copper|cyanoginosin LR|Dietary Fats|Ethanol|Folic Acid|Genistein|Glucose|hydroquinone|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|perfluorooctanoic acid|Plant Extracts|Quercetin|Raloxifene Hydrochloride|Resveratrol|sodium arsenite|Streptozocin|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution|Triclosan|Tunicamycin|Valproic Acid",1,PTEN
cell migration involved in sprouting angiogenesis,GO:0002042,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SIRT1
cell migration involved in vasculogenesis,GO:0035441,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
cell morphogenesis,GO:0000902,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,"Plant Extracts|theaflavin-3,3'-digallate",3,AHR|LIF|TGFB1
cell motility,GO:0048870,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,4-hydroxy-2-nonenal|bisphenol A|GW 501516,1,PTEN
cell population proliferation,GO:0008283,Non-alcoholic Fatty Liver Disease,MESH:D065626,80,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|3,4,5,3',4'-pentachlorobiphenyl|4-hydroxy-2-nonenal|Acetaminophen|Allopurinol|alpha-naphthoflavone|Arsenic Trioxide|Benzo(a)pyrene|Bile Acids and Salts|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Carvedilol|Cholesterol|Cholesterol, Dietary|cobaltiprotoporphyrin|cocoa butter|Copper|cyanoginosin LR|Dabigatran|Dextran Sulfate|Dietary Fats|Dietary Sucrose|Diethylnitrosamine|Dust|Ethanol|Eucalyptol|Fenofibrate|Folic Acid|Fructose|Genistein|Glucocorticoids|Glucose|Hydralazine|hydroquinone|Irinotecan|Iron|Linoleic Acid|Lipids|mancozeb|Maneb|Methionine|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Olanzapine|Oleic Acid|Orlistat|Palmitic Acid|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Phenylbutyrates|Pioglitazone|pirinixic acid|Plant Extracts|Plant Preparations|Prednisolone|Quercetin|Raloxifene Hydrochloride|Reactive Oxygen Species|Resveratrol|Rosiglitazone|S-Adenosylmethionine|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Sucrose|Tamoxifen|Taurine|Testosterone|Tetrachlorodibenzodioxin|Thioctic Acid|Tobacco Smoke Pollution|Toremifene|tributyltin|Triclosan|Tunicamycin|Valproic Acid",8,CSF2|IL3|LIF|PPARD|PPARG|PRKCA|PTEN|TGFB1
cell projection assembly,GO:0030031,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|Plant Extracts,0,
cell projection morphogenesis,GO:0048858,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|sodium arsenite,0,
cell projection organization,GO:0030030,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
cell proliferation in bone marrow,GO:0071838,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,1,ACE
cell redox homeostasis,GO:0045454,Non-alcoholic Fatty Liver Disease,MESH:D065626,35,"Acetaminophen|Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Cholesterol|Cholesterol, Dietary|Choline|Copper|Dietary Fats|Ethanol|Fenofibrate|Folic Acid|Fructose|geraniol|Glucose|hugan qingzhi|mancozeb|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Orlistat|Pioglitazone|Plant Extracts|Plant Preparations|Prednisolone|puerarin|Quercetin|Reactive Oxygen Species|Resveratrol|S-Adenosylmethionine|sodium arsenite|Streptozocin|Testosterone|Tobacco Smoke Pollution|tributyltin",4,ABCC2|NFE2L2|NQO1|PRDX3
cell-substrate adhesion,GO:0031589,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Raloxifene Hydrochloride|Triclosan,2,PPARD|PRKCE
cell surface pattern recognition receptor signaling pathway,GO:0002752,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CD14
cell surface receptor signaling pathway,GO:0007166,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,5,CD14|F2|LAMA1|TNFRSF1B|VLDLR
cellular aldehyde metabolic process,GO:0006081,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,ADH4|ALDH1A1
cellular amino acid homeostasis,GO:0080144,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Taurine,0,
cellular aromatic compound metabolic process,GO:0006725,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tetrachlorodibenzodioxin,0,
cellular biogenic amine catabolic process,GO:0042402,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Caffeine,0,
cellular cadmium ion homeostasis,GO:0006876,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
cellular calcium ion homeostasis,GO:0006874,Non-alcoholic Fatty Liver Disease,MESH:D065626,30,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|3,4,5,3',4'-pentachlorobiphenyl|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Choline|cyanoginosin LR|Dietary Fats|Ethanol|Fenofibrate|Folic Acid|Fructose|Genistein|Glucose|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Oleic Acid|Palmitic Acid|perfluorooctanoic acid|Plant Extracts|Quercetin|Resveratrol|sodium arsenite|Streptozocin|Tetrachlorodibenzodioxin|Thioctic Acid|Triclosan|Valproic Acid",3,PRKCA|STC2|TGFB1
cellular carbohydrate metabolic process,GO:0044262,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
cellular chemical homeostasis,GO:0055082,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
cellular chloride ion homeostasis,GO:0030644,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ABCC2
cellular component organization,GO:0016043,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Preparations,0,
cellular copper ion homeostasis,GO:0006878,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"3,4,5,3',4'-pentachlorobiphenyl|Copper|Streptozocin",0,
cellular defense response,GO:0006968,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRF1
cellular detoxification,GO:1990748,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
cellular detoxification of aldehyde,GO:0110095,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,ALDH1A1|ALDH2
cellular detoxification of hydrogen peroxide,GO:0061692,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Thioctic Acid,1,CAT
cellular detoxification of nitrogen compound,GO:0070458,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,GSTM1
cellular extravasation,GO:0045123,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNF
cellular glucose homeostasis,GO:0001678,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Bezafibrate|Glucose|sodium arsenite|Sodium Glutamate|Valproic Acid,2,NR1H4|SIRT1
cellular glutamate homeostasis,GO:0090461,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Blood Glucose,0,
cellular heat acclimation,GO:0070370,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
cellular hyperosmotic response,GO:0071474,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Sucrose,0,
cellular hyperosmotic salinity response,GO:0071475,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
cellular iron ion homeostasis,GO:0006879,Non-alcoholic Fatty Liver Disease,MESH:D065626,16,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|bisphenol A|Cadmium|Cadmium Chloride|Copper|Dietary Fats|Ethanol|gastrodin|Glucose|Iron|Oleic Acid|Palmitic Acid|Resveratrol|Streptozocin|Valproic Acid",0,
cellular lipid biosynthetic process,GO:0097384,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Palmitic Acid,0,
cellular lipid catabolic process,GO:0044242,Non-alcoholic Fatty Liver Disease,MESH:D065626,12,Arsenic Trioxide|Benzo(a)pyrene|Cadmium|Cadmium Chloride|Caffeine|Ethanol|Plant Extracts|Plant Preparations|Reactive Oxygen Species|Resveratrol|sodium arsenite|Streptozocin,0,
cellular lipid metabolic process,GO:0044255,Non-alcoholic Fatty Liver Disease,MESH:D065626,13,"bisphenol A|Cholesterol|Dietary Fats|Fatty Acids, Omega-3|Lipids|Oleic Acid|perfluorohexanesulfonic acid|perfluorooctanoic acid|Pioglitazone|Rosiglitazone|sodium arsenite|tributyltin|Triglycerides",0,
cellular metabolic process,GO:0044237,Non-alcoholic Fatty Liver Disease,MESH:D065626,63,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|Allopurinol|alpha-naphthoflavone|aroclor 1260|Arsenic Trioxide|Benzo(a)pyrene|Bile Acids and Salts|bisphenol A|Blood Glucose|Cadmium|Cadmium Chloride|Caffeine|Chromium|Copper|cyanoginosin LR|Dust|Ethanol|Fatty Acids, Omega-3|Folic Acid|Fructose|gastrodin|Genistein|Glucose|hydroquinone|Irinotecan|Iron|Linoleic Acid|mancozeb|Methionine|Niacin|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|obeticholic acid|Oleic Acid|Orlistat|Palmitates|Palmitic Acid|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Pioglitazone|pirinixic acid|Plant Extracts|Quercetin|Raloxifene Hydrochloride|Resveratrol|Rosiglitazone|S-Adenosylmethionine|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Tamoxifen|Taurine|Testosterone|Tetrachlorodibenzodioxin|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Triclosan|Tunicamycin|Valproic Acid",0,
cellular metal ion homeostasis,GO:0006875,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Cadmium Chloride|Iron,0,
cellular nitrogen compound metabolic process,GO:0034641,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride",0,
cellular oxidant detoxification,GO:0098869,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Reactive Oxygen Species,5,CAT|GSTA1|GSTP1|GSTT1|PRDX3
cellular pigment accumulation,GO:0043482,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
cellular potassium ion homeostasis,GO:0030007,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRKACA
cellular respiration,GO:0045333,Non-alcoholic Fatty Liver Disease,MESH:D065626,21,4-hydroxy-2-nonenal|alpha-naphthoflavone|Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Dietary Fats|Folic Acid|Fructose|Glucose|hydroquinone|Palmitic Acid|Quercetin|Resveratrol|Rosiglitazone|Streptozocin|Tetrachlorodibenzodioxin|Thioctic Acid|Triclosan|Valproic Acid,1,CYP1A2
"cellular response to 2,3,7,8-tetrachlorodibenzodioxine",GO:1904613,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Benzo(a)pyrene|Tetrachlorodibenzodioxin,1,AHR
"cellular response to 3,3',5-triiodo-L-thyronine",GO:1905243,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PNPLA3
cellular response to 3-methylcholanthrene,GO:1904682,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR
cellular response to acetaldehyde,GO:1905641,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
cellular response to aldehyde,GO:0110096,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Extracts,0,
cellular response to aldosterone,GO:1904045,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ACE
cellular response to alkaloid,GO:0071312,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
cellular response to amino acid starvation,GO:0034198,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
cellular response to amino acid stimulus,GO:0071230,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,TNF|XBP1
cellular response to ammonium ion,GO:0071242,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
cellular response to amyloid-beta,GO:1904646,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,SIRT1|TNF
cellular response to angiotensin,GO:1904385,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,MRTFA|NFE2L2|PRKCD
cellular response to antibiotic,GO:0071236,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Bile Acids and Salts,4,CYP17A1|IL1B|SIRT1|XBP1
cellular response to Aroclor 1254,GO:1904011,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
cellular response to arsenic-containing substance,GO:0071243,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Arsenic Trioxide|Resveratrol|sodium arsenite,0,
cellular response to arsenite(3-),GO:1903841,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Methionine,0,
cellular response to bile acid,GO:1903413,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,ABCB4|NR1H4
cellular response to blue light,GO:0071483,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Plant Extracts|Resveratrol,0,
cellular response to cadmium ion,GO:0071276,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,1,CYP1A2
cellular response to cAMP,GO:0071320,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,ADIPOQ|AHR
cellular response to carbohydrate stimulus,GO:0071322,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRKCA
cellular response to cell-matrix adhesion,GO:0071460,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,GSTP1
cellular response to chemical stimulus,GO:0070887,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Folic Acid,0,
cellular response to chemical stress,GO:0062197,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,gypenoside LXXV,0,
cellular response to chromate,GO:0071247,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Chromium|sodium arsenite,0,
cellular response to cisplatin,GO:0072719,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|sodium arsenite",0,
cellular response to cobalt ion,GO:0071279,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
cellular response to cold,GO:0070417,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Lipids|tributyltin,1,PRKACA
cellular response to copper ion,GO:0071280,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Copper,2,CYP1A2|NFE2L2
cellular response to curcumin,GO:1904644,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SIRT1
cellular response to cytokine stimulus,GO:0071345,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
cellular response to decreased oxygen levels,GO:0036294,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
cellular response to dexamethasone stimulus,GO:0071549,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,ABCC2|AHR|JAK2|TGFB1
cellular response to diacyl bacterial lipopeptide,GO:0071726,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CD14
cellular response to DNA damage stimulus,GO:0006974,Non-alcoholic Fatty Liver Disease,MESH:D065626,49,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|3,4,5,3',4'-pentachlorobiphenyl|4-hydroxy-2-nonenal|Acetaminophen|alpha-naphthoflavone|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Carvedilol|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Fats|Dietary Sucrose|Diethylnitrosamine|Dimethylnitrosamine|Ethanol|Eucalyptol|Folic Acid|Genistein|Glucose|Hydralazine|hydroquinone|Irinotecan|Iron|mancozeb|Maneb|Methionine|Niacin|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Palmitic Acid|perfluorooctanoic acid|Plant Extracts|Plant Preparations|Quercetin|Resveratrol|Silymarin|sodium arsenite|Streptozocin|Tamoxifen|Taurine|Tobacco Smoke Pollution|Triclosan|Tunicamycin|Valproic Acid",3,IKBKG|PRKCD|SIRT1
cellular response to electrical stimulus,GO:0071257,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
cellular response to epidermal growth factor stimulus,GO:0071364,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Genistein,1,GSTP1
cellular response to epinephrine stimulus,GO:0071872,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,ADIPOQ|PRKACA
cellular response to estradiol stimulus,GO:0071392,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ESR1
cellular response to estrogen stimulus,GO:0071391,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Genistein,2,ESR1|FAS
cellular response to ethanol,GO:0071361,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,PRKCE|PTEN
cellular response to fatty acid,GO:0071398,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Palmitic Acid|Reactive Oxygen Species,8,ALDH2|CPT1A|IL1B|LDLR|NR1H4|PDK4|PRKCD|SREBF1
cellular response to fluid shear stress,GO:0071498,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,MMP1|NFE2L2|XBP1
cellular response to fluoride,GO:1902618,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"Arsenic Trioxide|bisphenol A|theaflavin-3,3'-digallate",0,
cellular response to folic acid,GO:0071231,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FOLR2
cellular response to food,GO:0071240,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
cellular response to forskolin,GO:1904322,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR
cellular response to fructose stimulus,GO:0071332,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,PPARA|XBP1
cellular response to gamma radiation,GO:0071480,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Reactive Oxygen Species,0,
cellular response to glucagon stimulus,GO:0071377,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,FGF21|PRKACA
cellular response to glucocorticoid stimulus,GO:0071385,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,AHR|GSTP1
cellular response to glucose starvation,GO:0042149,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,5,NFE2L2|PRKCD|SIRT1|VLDLR|XBP1
cellular response to glucose stimulus,GO:0071333,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,6,ACE|FGF21|IL1B|PRKACA|TGFB1|XBP1
cellular response to gonadotropin stimulus,GO:0071371,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP17A1
cellular response to granulocyte macrophage colony-stimulating factor stimulus,GO:0097011,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CSF2
cellular response to growth factor stimulus,GO:0071363,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,CAT|TGFB1|TNFRSF1B
cellular response to heat,GO:0034605,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|sodium arsenite,2,IL1A|PRKACA
cellular response to hormone stimulus,GO:0032870,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH2
cellular response to hydrogen peroxide,GO:0070301,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,"Glucose|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride",5,FAS|NFE2L2|NQO1|PRKCD|SIRT1
cellular response to hydroperoxide,GO:0071447,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRKCD
cellular response to hydrostatic pressure,GO:0071464,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
cellular response to hyperoxia,GO:0071455,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,FAS|PPARG
cellular response to hypoxia,GO:0071456,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Genistein|Plant Extracts|Quercetin|Resveratrol,11,B3GAT1|FAS|NFE2L2|PPARD|PPARG|PRKCE|PTEN|SIRT1|STC2|TGFB1|VLDLR
cellular response to inorganic substance,GO:0071241,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide,0,
cellular response to insulin-like growth factor stimulus,GO:1990314,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,PTEN|TGFB1
cellular response to insulin stimulus,GO:0032869,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Plant Extracts|Resveratrol|Streptozocin,13,ADIPOQ|GPT|GSTP1|LEP|PNPLA3|PPARG|PRKCD|PTEN|SIRT1|SREBF1|TRIB3|VLDLR|XBP1
cellular response to interleukin-1,GO:0071347,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,5,ABCC2|FAS|MMP1|TNFRSF1B|VLDLR
cellular response to interleukin-17,GO:0097398,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL1B
cellular response to interleukin-3,GO:0036016,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
cellular response to interleukin-4,GO:0071353,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,XBP1
cellular response to interleukin-6,GO:0071354,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ABCC2
cellular response to interleukin-7,GO:0098761,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ATP5F1B
cellular response to ionizing radiation,GO:0071479,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,"Genistein|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Plant Extracts|Reactive Oxygen Species|Resveratrol",3,SIRT1|TGFB1|TNF
cellular response to iron(III) ion,GO:0071283,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
cellular response to laminar fluid shear stress,GO:0071499,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,NFE2L2|XBP1
cellular response to L-ascorbic acid,GO:0071298,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LEP
cellular response to lectin,GO:1990858,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
cellular response to leptin stimulus,GO:0044320,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,LEP|PTEN
cellular response to leukemia inhibitory factor,GO:1990830,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,NR5A2|SIRT1|XBP1
cellular response to light stimulus,GO:0071482,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Blood Glucose,0,
cellular response to lipid,GO:0071396,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL1B
cellular response to lipopolysaccharide,GO:0071222,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Plant Extracts|Quercetin|sodium arsenite,17,ABCC2|CD14|CSF2|CYP17A1|GSTP1|IL1A|IL1B|IL1RN|JAK2|MMP1|NLRP3|NR1H4|PPARD|TNF|TNFRSF1B|VLDLR|XBP1
cellular response to lipoteichoic acid,GO:0071223,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CD14
cellular response to lithium ion,GO:0071285,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,FAS|PPARG
cellular response to low-density lipoprotein particle stimulus,GO:0071404,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,FGF21|LDLR|PPARG|TGFB1
cellular response to mechanical stimulus,GO:0071260,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,F2|FAS|IL1B|TGFB1
cellular response to mercury ion,GO:0071288,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL4
cellular response to metal ion,GO:0071248,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NQO1
cellular response to methionine,GO:0061431,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NFE2L2
cellular response to molecule of bacterial origin,GO:0071219,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,AHR|CD14|IL1B|TNF
cellular response to nerve growth factor stimulus,GO:1990090,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
cellular response to nicotine,GO:0071316,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNF
cellular response to nitrosative stress,GO:0071500,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
cellular response to norepinephrine stimulus,GO:0071874,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL1RN
cellular response to nutrient,GO:0031670,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,XBP1
cellular response to nutrient levels,GO:0031669,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|sodium arsenite|Tunicamycin,1,PPARD
cellular response to organic cyclic compound,GO:0071407,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"3,4,5,3',4'-pentachlorobiphenyl|Benzo(a)pyrene|Ethanol",0,
cellular response to oxidative stress,GO:0034599,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|4-hydroxy-2-nonenal|Arsenic Trioxide|Cadmium|Ethanol|Plant Extracts|Reactive Oxygen Species|Resveratrol|sodium arsenite,5,NFE2L2|NQO1|PRDX3|PRKCD|XBP1
cellular response to parathyroid hormone stimulus,GO:0071374,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRKACA
cellular response to peptide,GO:1901653,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ATP5F1B
cellular response to peptide hormone stimulus,GO:0071375,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,MMP1|XBP1
cellular response to peptidoglycan,GO:0071224,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NLRP3
cellular response to phenylalanine,GO:0071234,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
cellular response to platelet-derived growth factor stimulus,GO:0036120,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,3,PPARG|PRKCE|RDX
cellular response to prostaglandin E stimulus,GO:0071380,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,PPARG|PRKCE
cellular response to prostaglandin stimulus,GO:0071379,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PPARG
cellular response to radiation,GO:0071478,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Folic Acid,0,
cellular response to reactive oxygen species,GO:0034614,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Arsenic Trioxide|Genistein|Quercetin|Reactive Oxygen Species,1,PRDX3
cellular response to redox state,GO:0071461,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Reactive Oxygen Species|sodium arsenite,0,
cellular response to resveratrol,GO:1904639,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,ALDH2|SIRT1
cellular response to retinoic acid,GO:0071300,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,LEP|MRTFA|PPARG|TNF
cellular response to rotenone,GO:1904648,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SIRT1
cellular response to sodium arsenite,GO:1903936,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
cellular response to sorbitol,GO:0072709,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
cellular response to starvation,GO:0009267,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,5,GNMT|PDK4|PPARA|SIRT1|SREBF1
cellular response to stress,GO:0033554,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Cadmium|Cadmium Chloride|Copper|sodium arsenite,1,PRDX3
cellular response to thyroid hormone stimulus,GO:0097067,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RDX
cellular response to toxic substance,GO:0097237,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Benzo(a)pyrene|Quercetin|Reactive Oxygen Species|Resveratrol|sodium arsenite|Tetrachlorodibenzodioxin,2,AHR|TNF
cellular response to transforming growth factor beta stimulus,GO:0071560,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,MRTFA|TGFB1
cellular response to triacyl bacterial lipopeptide,GO:0071727,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CD14
cellular response to tumor necrosis factor,GO:0071356,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,6,ABCC2|FAS|MMP1|NFE2L2|SIRT1|TNFRSF1B
cellular response to type II interferon,GO:0071346,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,FAS|TNF
cellular response to UV,GO:0034644,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Quercetin|sodium arsenite,1,PRKCD
cellular response to UV-A,GO:0071492,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Extracts,1,MMP1
cellular response to UV-B,GO:0071493,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Arsenic Trioxide|Quercetin|Reactive Oxygen Species|Resveratrol|Rosiglitazone|sodium arsenite,0,
cellular response to UV-C,GO:0071494,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
cellular response to vascular endothelial growth factor stimulus,GO:0035924,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,XBP1
cellular response to virus,GO:0098586,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Resveratrol|sodium arsenite|Tetrachlorodibenzodioxin,3,JAK2|NLRP3|TGFB1
cellular response to vitamin B3,GO:0071303,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SIRT1
cellular response to vitamin D,GO:0071305,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
cellular response to vitamin E,GO:0071306,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,1,PPARG
cellular response to wortmannin,GO:1904568,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ESR1
cellular response to xenobiotic stimulus,GO:0071466,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,bisphenol A|Choline|geraniol|Glucose|Lipids|Oleic Acid|Rosiglitazone|Tamoxifen|Triclosan,10,ABCC2|ADIPOQ|AHR2|FGF21|GSTM1|IL1B|MMP1|NFE2L2|NQO1|NR1H4
cellular response to X-ray,GO:0071481,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Arsenic Trioxide|Caffeine|Reactive Oxygen Species,0,
cellular senescence,GO:0090398,Non-alcoholic Fatty Liver Disease,MESH:D065626,23,"Arsenic Trioxide|bisphenol A|Cadmium Chloride|Caffeine|Dietary Fats|Dietary Sucrose|Diethylnitrosamine|Folic Acid|Fructose|Genistein|Glucose|Irinotecan|mancozeb|Maneb|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Plant Extracts|Resveratrol|sodium arsenite|Streptozocin|Tetrachlorodibenzodioxin|Tunicamycin|Valproic Acid",1,PRKCD
cellular sodium ion homeostasis,GO:0006883,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,1,IL1A
cellular transition metal ion homeostasis,GO:0046916,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
cellular triglyceride homeostasis,GO:0035356,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Oleic Acid|Triglycerides,3,NR1H4|SIRT1|XBP1
cellular zinc ion homeostasis,GO:0006882,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"3,4,5,3',4'-pentachlorobiphenyl|Cadmium Chloride|Copper|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride",0,
cell volume homeostasis,GO:0006884,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Iron|Quercetin|sodium arsenite|Tamoxifen|tectorigenin,0,
central nervous system development,GO:0007417,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,GSTP1|PTEN
central nervous system myelination,GO:0022010,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
central nervous system myelin maintenance,GO:0032286,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium Chloride|sodium arsenite,1,PTEN
central nervous system neuron axonogenesis,GO:0021955,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,PRKCA|PTEN
central nervous system neuron development,GO:0021954,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LEP
central nervous system neuron differentiation,GO:0021953,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
centriole replication,GO:0007099,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
centrosome duplication,GO:0051298,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Tamoxifen,0,
ceramide 1-phosphate transport,GO:1902389,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MTTP
ceramide biosynthetic process,GO:0046513,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Tetrachlorodibenzodioxin,0,
ceramide metabolic process,GO:0006672,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,"3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|perfluorooctanoic acid|sodium arsenite|Streptozocin|Tunicamycin",0,
cerebellar Purkinje cell differentiation,GO:0021702,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
cerebral cortex development,GO:0021987,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Reactive Oxygen Species,1,VLDLR
cGMP biosynthetic process,GO:0006182,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Quercetin|Resveratrol|sodium arsenite|Streptozocin,0,
cGMP-mediated signaling,GO:0019934,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
cGMP metabolic process,GO:0046068,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Raloxifene Hydrochloride|Streptozocin,0,
chaperone-mediated protein complex assembly,GO:0051131,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
chemical homeostasis,GO:0048878,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,0,
chemical synaptic transmission,GO:0007268,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Olanzapine,1,ACE
"chemical synaptic transmission, postsynaptic",GO:0099565,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Orlistat,0,
chemokine (C-C motif) ligand 17 production,GO:0044809,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Extracts,0,
chemosensory behavior,GO:0007635,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,alpha-naphthoflavone|Benzo(a)pyrene|Caffeine|Eucalyptol|Genistein|Quercetin|Resveratrol|Valproic Acid,1,PRKCE
chemotaxis,GO:0006935,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Glucose|Valproic Acid,0,
chloride ion homeostasis,GO:0055064,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Resveratrol,0,
chloride transmembrane transport,GO:1902476,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tamoxifen,0,
chloride transport,GO:0006821,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Quercetin|Resveratrol,0,
cholecystokinin signaling pathway,GO:0038188,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Extracts,0,
cholesterol biosynthetic process,GO:0006695,Non-alcoholic Fatty Liver Disease,MESH:D065626,45,"3,4,5,3',4'-pentachlorobiphenyl|Allopurinol|Arsenic Trioxide|Bezafibrate|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Cholesterol|Cholesterol, Dietary|Choline|Dietary Carbohydrates|Dietary Fats|Dietary Sucrose|Dietary Sugars|Diethylnitrosamine|Ethanol|Eucalyptol|Fatty Acids, Omega-3|Fenofibrate|Fructose|Genistein|geraniol|Linoleic Acid|mancozeb|Methionine|Niacin|Oleic Acid|Palmitic Acid|perfluorohexanesulfonic acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Plant Preparations|Quercetin|Resveratrol|Rosiglitazone|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Sucrose|Taurine|Tetrachlorodibenzodioxin|tributyltin",1,SREBF1
cholesterol catabolic process,GO:0006707,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SCARB1
cholesterol efflux,GO:0033344,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,"Cholesterol|Cholesterol, Dietary|Ethanol|Lipids|Plant Preparations|sodium arsenite",1,SCARB1
cholesterol homeostasis,GO:0042632,Non-alcoholic Fatty Liver Disease,MESH:D065626,43,"5-(3-methoxy-5-(4-methoxystyryl)phenoxy)-2,2-dimethylpentanoic acid|Arsenic Trioxide|Bile Acids and Salts|bisphenol A|carnosol|Cholesterol|Cholesterol, Dietary|Choline|Chromium|Copper|Dietary Carbohydrates|Dietary Fats|Dietary Sucrose|Ethanol|Fatty Acids, Omega-3|Fenofibrate|Folic Acid|Fructose|Genistein|geraniol|Methionine|obeticholic acid|Olanzapine|Oleic Acid|Orlistat|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Plant Preparations|Quercetin|Resveratrol|Rosiglitazone|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Taurine|tectorigenin|Thioctic Acid|Tobacco Smoke Pollution|tuberostemonine",7,LDLR|MTTP|NR1H4|NR5A2|SCARB1|SIRT1|XBP1
cholesterol import,GO:0070508,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,LDLR|SCARB1
cholesterol metabolic process,GO:0008203,Non-alcoholic Fatty Liver Disease,MESH:D065626,55,"2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine|3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|aroclor 1260|Arsenic Trioxide|Benzo(a)pyrene|Bezafibrate|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Cholesterol|Cholesterol, Dietary|Choline|Chromium|cyanoginosin LR|Dietary Fats|Dietary Sucrose|Dietary Sugars|Dimethylnitrosamine|Dust|Ethanol|Fatty Acids, Omega-3|Fenofibrate|flavangenol|Folic Acid|Fructose|geraniol|Glucose|Iron|mancozeb|Methionine|Niacinamide|obeticholic acid|Oleic Acid|Olive Oil|omaveloxolone|osteum|Palmitic Acid|Palm Oil|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Quercetin|Resveratrol|Silymarin|sodium arsenite|Streptozocin|Tetrachlorodibenzodioxin|Thioctic Acid|Tobacco Smoke Pollution|Triclosan|Valproic Acid",9,CAT|CYP1A2|IL4|LDLR|LEP|MTTP|PPARD|SREBF1|VLDLR
cholesterol transport,GO:0030301,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|tectorigenin,2,LDLR|SCARB1
choline biosynthetic process,GO:0042425,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Arsenic Trioxide|Dietary Fats|perfluorooctanoic acid,0,
choline catabolic process,GO:0042426,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ACE
choline metabolic process,GO:0019695,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Choline|geraniol|sodium arsenite,1,ACE
choline transport,GO:0015871,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Choline,0,
chondrocyte differentiation,GO:0002062,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,2,PRKCA|TGFB1
chondroitin sulfate biosynthetic process,GO:0030206,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
chondroitin sulfate proteoglycan biosynthetic process,GO:0050650,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,B3GAT1
chordate embryonic development,GO:0043009,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,FAS|FTO
chorionic trophoblast cell differentiation,GO:0060718,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
chromatin organization,GO:0006325,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Cadmium Chloride|Resveratrol|sodium arsenite|Sodium Glutamate,3,JAK2|RAG2|SIRT1
chromatin remodeling,GO:0006338,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Arsenic Trioxide|bisphenol A|Glucose|Rosiglitazone|sodium arsenite,6,EIF2AK1|ESR1|JAK2|NR5A2|PRKCA|PTEN
chromosome condensation,GO:0030261,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Plant Extracts|sodium arsenite",0,
chromosome localization,GO:0050000,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,"bisphenol A|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride",0,
chromosome organization,GO:0051276,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,alpha-naphthoflavone|hydroquinone|sodium arsenite,0,
chromosome organization involved in meiotic cell cycle,GO:0070192,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,alpha-naphthoflavone,0,
chromosome segregation,GO:0007059,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
chronic inflammatory response to antigenic stimulus,GO:0002439,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,AHCY|IL1B|IL1RN|TNF
chylomicron assembly,GO:0034378,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MTTP
ciliary basal body organization,GO:0032053,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium Chloride,0,
cilium assembly,GO:0060271,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tobacco Smoke Pollution,1,FTO
cilium movement,GO:0003341,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tobacco Smoke Pollution,0,
cilium organization,GO:0044782,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tobacco Smoke Pollution,0,
cinnamic acid metabolic process,GO:0009803,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,0,
circadian regulation of gene expression,GO:0032922,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Cadmium Chloride|Dietary Fats|Resveratrol|Valproic Acid,3,AHR|PPARA|SIRT1
circadian rhythm,GO:0007623,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Ethanol,9,ADIPOQ|AHR|FAS|LEP|MTTP|PRF1|SIRT1|SREBF1|TNF
circadian sleep/wake cycle,GO:0042745,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Triclosan,1,AHCY
circulatory system process,GO:0003013,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tobacco Smoke Pollution,0,
circumferential growth involved in left ventricle morphogenesis,GO:0003243,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR
citrate metabolic process,GO:0006101,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Dextran Sulfate|perfluorooctanoic acid|Resveratrol|Streptozocin,0,
citrate transport,GO:0015746,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
citrulline biosynthetic process,GO:0019240,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Irinotecan,0,
CMP metabolic process,GO:0046035,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
cobalamin metabolic process,GO:0009235,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
coenzyme A metabolic process,GO:0015936,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium Chloride|Dietary Fats,0,
cognition,GO:0050890,Non-alcoholic Fatty Liver Disease,MESH:D065626,14,"Acetaminophen|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Cholesterol, Dietary|Dietary Fats|Ethanol|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Pioglitazone|Quercetin|Tobacco Smoke Pollution",2,INS|TNF
cold acclimation,GO:0009631,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ATP5F1B
cold-induced thermogenesis,GO:0106106,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,1,PPARG
collagen-activated signaling pathway,GO:0038065,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,1,JAK2
collagen biosynthetic process,GO:0032964,Non-alcoholic Fatty Liver Disease,MESH:D065626,18,Acetaminophen|Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|cyanoginosin LR|Dietary Fats|Dimethylnitrosamine|Ethanol|Linoleic Acid|Oleic Acid|Olive Oil|Prednisolone|Quercetin|Resveratrol|sodium arsenite|Streptozocin|tributyltin,0,
collagen catabolic process,GO:0030574,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
collagen fibril organization,GO:0030199,Non-alcoholic Fatty Liver Disease,MESH:D065626,33,"3,4,5,3',4'-pentachlorobiphenyl|Allopurinol|bisphenol A|Cadmium|Cadmium Chloride|Cholesterol, Dietary|Choline|cyanoginosin LR|Dietary Fats|Dietary Sucrose|Dietary Sugars|Diethylnitrosamine|Dimethylnitrosamine|Ethanol|Fenofibrate|Folic Acid|Fructose|hydroquinone|Methionine|omaveloxolone|Palm Oil|Pioglitazone|Prednisolone|Quercetin|Raloxifene Hydrochloride|Resveratrol|sodium arsenite|Streptozocin|Tamoxifen|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Valproic Acid",0,
collagen metabolic process,GO:0032963,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Dimethylnitrosamine|puerarin|Silymarin,1,PRKCD
colon epithelial cell migration,GO:0061580,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
columnar/cuboidal epithelial cell maturation,GO:0002069,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Eucalyptol,1,TGFB1
common myeloid progenitor cell proliferation,GO:0035726,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,1,GSTP1
complement activation,GO:0006956,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Acetaminophen,0,
"complement activation, classical pathway",GO:0006958,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,C1QC
compound eye morphogenesis,GO:0001745,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RDX
conditioned place preference,GO:1990708,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
conditioned taste aversion,GO:0001661,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR
connective tissue development,GO:0061448,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
connective tissue replacement involved in inflammatory response wound healing,GO:0002248,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tetrachlorodibenzodioxin,2,IL1A|TGFB1
contact inhibition,GO:0060242,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"3,4,5,3',4'-pentachlorobiphenyl|Cadmium Chloride|sodium arsenite|Tetrachlorodibenzodioxin",1,AHR
copper ion homeostasis,GO:0055070,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,"3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|Cadmium|Cadmium Chloride|Copper|Ethanol|Fructose|sodium arsenite",0,
copper ion transport,GO:0006825,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
copulation,GO:0007620,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
cornea development in camera-type eye,GO:0061303,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LAMA1
cortical actin cytoskeleton organization,GO:0030866,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNF
corticosteroid hormone secretion,GO:0035930,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Sodium Glutamate,0,
corticosterone secretion,GO:0035934,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|Cadmium|Cadmium Chloride|Caffeine|perfluorooctanoic acid|Sodium Glutamate,0,
corticotropin-releasing hormone secretion,GO:0043396,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,perfluoro-n-nonanoic acid|perfluorooctanoic acid,0,
cortisol metabolic process,GO:0034650,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Cadmium Chloride|Ethanol,0,
cortisol secretion,GO:0043400,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,0,
courtship behavior,GO:0007619,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
cranial skeletal system development,GO:1904888,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Ethanol|Folic Acid|Valproic Acid,1,AHR2
creatine biosynthetic process,GO:0006601,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Dietary Fats|Diethylnitrosamine|perfluorooctanoic acid|Plant Extracts|sodium arsenite|Streptozocin,0,
creatine metabolic process,GO:0006600,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Dextran Sulfate|Dietary Fats|perfluorooctanoic acid|Plant Extracts,0,
creatinine catabolic process,GO:0006602,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Blood Glucose|Cadmium Chloride,0,
creatinine metabolic process,GO:0046449,Non-alcoholic Fatty Liver Disease,MESH:D065626,32,"Acetaminophen|Allopurinol|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Blood Glucose|Cadmium|Cadmium Chloride|Cholesterol, Dietary|cobaltiprotoporphyrin|Dietary Fats|Dietary Sucrose|Dietary Sugars|Diethylnitrosamine|Fatty Acids, Omega-3|Fenofibrate|Folic Acid|Fructose|Glucose|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Palmitic Acid|Pioglitazone|Plant Extracts|Plant Preparations|Quercetin|Resveratrol|Rosiglitazone|Silymarin|sodium arsenite|Streptozocin|Tunicamycin|Valproic Acid",0,
CTP metabolic process,GO:0046036,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
cumulus cell differentiation,GO:0001549,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
cyclooxygenase pathway,GO:0019371,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Quercetin|Resveratrol|Tobacco Smoke Pollution,0,
cysteine biosynthetic process,GO:0019344,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Arsenic Trioxide|Irinotecan|Taurine,0,
cysteine metabolic process,GO:0006534,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Benzo(a)pyrene|Cadmium|Cadmium Chloride|Dextran Sulfate|sodium arsenite|Thioctic Acid,0,
cytidine biosynthetic process,GO:0046088,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
cytochrome c biosynthetic process,GO:1903607,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
cytokine-mediated signaling pathway,GO:0019221,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,6,IL1A|IL1B|IL1RN|IL3|JAK2|PRKACA
cytokine production,GO:0001816,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,1,NQO1
cytokine production involved in immune response,GO:0002367,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tobacco Smoke Pollution,0,
cytokine production involved in inflammatory response,GO:0002534,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,bisphenol A|Coal|Iron|perfluorooctanoic acid|Rosiglitazone|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution,0,
cytokinesis,GO:0000910,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride",0,
cytolysis,GO:0019835,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium Chloride,0,
cytolysis by host of symbiont cells,GO:0051838,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,F2
cytoplasmic sequestering of NF-kappaB,GO:0007253,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,alpha-naphthoflavone|Blood Glucose|Eucalyptol|Resveratrol|Silymarin,0,
cytoplasmic sequestering of transcription factor,GO:0042994,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
cytoplasm organization,GO:0007028,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
cytosine metabolic process,GO:0019858,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|perfluorooctanoic acid,0,
cytoskeleton organization,GO:0007010,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
cytosolic lipolysis,GO:0061725,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"3,4,5,3',4'-pentachlorobiphenyl",0,
D-aspartate import across plasma membrane,GO:0070779,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRKCD
decidualization,GO:0046697,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Benzo(a)pyrene|bisphenol A|Copper|Genistein,4,ESR1|LIF|PPARD|STC2
defense response,GO:0006952,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,NLRP3|TGFB1|TNF
defense response to bacterium,GO:0042742,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|sodium arsenite,6,IKBKG|IL1B|NR1H4|PRKCD|RAG2|TNF
defense response to fungus,GO:0050832,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
defense response to Gram-negative bacterium,GO:0050829,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,1,TNFRSF1B
defense response to Gram-positive bacterium,GO:0050830,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,4,IL1B|NLRP3|TNF|TNFRSF1B
defense response to protozoan,GO:0042832,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,IL4|TNFRSF1B
defense response to symbiont,GO:0140546,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
defense response to tumor cell,GO:0002357,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRF1
defense response to virus,GO:0051607,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"bisphenol A|S-Adenosylmethionine|Tetrachlorodibenzodioxin|theaflavin-3,3'-digallate",3,NLRP3|PRF1|TNFRSF1B
dehydroepiandrosterone secretion,GO:0035942,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
delamination,GO:0060232,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tobacco Smoke Pollution,0,
dendrite arborization,GO:0140059,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|sodium arsenite|Tetrachlorodibenzodioxin|Valproic Acid,0,
dendrite development,GO:0016358,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,1,LAMA1
dendrite extension,GO:0097484,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
dendrite morphogenesis,GO:0048813,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,VLDLR
dendrite regeneration,GO:0031104,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,FAS|PTEN
dendritic cell differentiation,GO:0097028,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Preparations,2,CSF2|IL4
dendritic cell homeostasis,GO:0036145,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,sodium arsenite|Tetrachlorodibenzodioxin,0,
dendritic cell proliferation,GO:0044565,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Dextran Sulfate|perfluorooctanoic acid,0,
dendritic spine development,GO:0060996,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
dendritic spine maintenance,GO:0097062,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
dendritic spine morphogenesis,GO:0060997,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
dentate gyrus development,GO:0021542,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Valproic Acid,1,PTEN
dentin mineralization,GO:0097188,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
deoxyadenosine metabolic process,GO:0046090,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,0,
deoxyguanosine biosynthetic process,GO:0042452,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Cholesterol|Dietary Fats,0,
deoxyguanosine metabolic process,GO:0042453,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Iron,0,
dephosphorylation,GO:0016311,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
dermatan sulfate biosynthetic process,GO:0030208,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
desmosome assembly,GO:0002159,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRKCA
detection of biotic stimulus,GO:0009595,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NLRP3
detection of carbon dioxide,GO:0003031,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Palmitic Acid,0,
detection of chemical stimulus involved in sensory perception,GO:0050907,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,geraniol,0,
detection of chemical stimulus involved in sensory perception of taste,GO:0050912,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
detection of glucose,GO:0051594,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Dietary Fats|Dietary Sucrose|Glucose,0,
detection of host,GO:0044405,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Eucalyptol,0,
detection of lipopolysaccharide,GO:0032497,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SCARB1
detection of mechanical stimulus involved in sensory perception of pain,GO:0050966,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,sodium arsenite|Streptozocin,1,TNF
detection of oxidative stress,GO:0070994,Non-alcoholic Fatty Liver Disease,MESH:D065626,55,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|3,4,5,3',4'-pentachlorobiphenyl|4-hydroxy-2-nonenal|Acetaminophen|alpha-naphthoflavone|Arsenic Trioxide|Benzo(a)pyrene|Bezafibrate|bisphenol A|bromodichloromethane|Cadmium|Cadmium Chloride|Carvedilol|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Fats|Dietary Sugars|Diethylnitrosamine|Dust|Ethanol|Fatty Acids, Omega-3|Fenofibrate|Folic Acid|Fructose|gastrodin|geraniol|Glucose|hydroquinone|Iron|Methionine|Niacin|Niacinamide|Palmitic Acid|Pioglitazone|Plant Extracts|Plant Preparations|puerarin|Quercetin|Reactive Oxygen Species|Resveratrol|Rosiglitazone|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Sucrose|Tamoxifen|Taurine|Tetrachlorodibenzodioxin|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Triclosan|Valproic Acid",1,ADIPOQ
detection of renal blood flow,GO:0002000,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Folic Acid,0,
detection of symbiotic bacterium,GO:0009604,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,0,
detection of temperature stimulus involved in sensory perception of pain,GO:0050965,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Streptozocin,0,
detection of tumor cell,GO:0002355,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,0,
determination of adult lifespan,GO:0008340,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,"bisphenol A|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Plant Extracts|Resveratrol|sodium arsenite",4,CAT|GNMT|LEP|SIRT1
determination of left/right symmetry,GO:0007368,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TRIB3
detoxification,GO:0098754,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|geraniol|sodium arsenite,0,
detoxification of arsenic-containing substance,GO:0071722,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|Folic Acid,0,
detoxification of mercury ion,GO:0050787,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ABCC2
developmental growth,GO:0048589,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,Benzo(a)pyrene|bisphenol A|Cadmium|Chromium|Folic Acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Tobacco Smoke Pollution,0,
developmental growth involved in morphogenesis,GO:0060560,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Benzo(a)pyrene|Copper,0,
developmental pigmentation,GO:0048066,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
developmental process,GO:0032502,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,aroclor 1260|bisphenol A|sodium arsenite|Thioctic Acid,0,
developmental process involved in reproduction,GO:0003006,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Chromium|perfluorooctanoic acid|sodium arsenite,0,
dGMP biosynthetic process,GO:0006181,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
diacylglycerol biosynthetic process,GO:0006651,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
diacylglycerol metabolic process,GO:0046339,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,"3,4,5,3',4'-pentachlorobiphenyl|Choline|Methionine|perfluoro-n-nonanoic acid|tributyltin",0,
diakinesis,GO:0000241,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
dibenzo-p-dioxin metabolic process,GO:0018894,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP1A2
dicarboxylic acid metabolic process,GO:0043648,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
dichloromethane metabolic process,GO:0018900,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,GSTT1
diestrus,GO:0060207,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Acetaminophen|bisphenol A|tributyltin,0,
diet induced thermogenesis,GO:0002024,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,perfluorooctanoic acid|Sodium Glutamate,1,PPARG
digestion,GO:0007586,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MTTP
digestive system process,GO:0022600,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
digestive tract development,GO:0048565,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,NR1H4|NR5A2|TGFB1
disaccharide metabolic process,GO:0005984,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
diterpenoid metabolic process,GO:0016101,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,0,
DN2 thymocyte differentiation,GO:1904155,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RAG2
DNA amplification,GO:0006277,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
DNA biosynthetic process,GO:0071897,Non-alcoholic Fatty Liver Disease,MESH:D065626,11,Arsenic Trioxide|bisphenol A|Dietary Fats|Folic Acid|geraniol|Orlistat|Pioglitazone|Quercetin|Resveratrol|Rosiglitazone|Triclosan,0,
DNA catabolic process,GO:0006308,Non-alcoholic Fatty Liver Disease,MESH:D065626,11,Acetaminophen|Cadmium|Cadmium Chloride|Copper|cyanoginosin LR|Diethylnitrosamine|hydroquinone|Niacin|Plant Extracts|Resveratrol|Tetrachlorodibenzodioxin,0,
"DNA catabolic process, endonucleolytic",GO:0000737,Non-alcoholic Fatty Liver Disease,MESH:D065626,26,"4-hydroxy-2-nonenal|Acetaminophen|Allopurinol|Benzo(a)pyrene|bisphenol A|Blood Glucose|Cadmium|Cadmium Chloride|Caffeine|Copper|Dietary Fats|Diethylnitrosamine|Ethanol|Glucose|Irinotecan|Iron|mancozeb|Maneb|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Reactive Oxygen Species|Resveratrol|Silymarin|sodium arsenite|Streptozocin|Thioctic Acid|Valproic Acid",0,
DNA damage checkpoint signaling,GO:0000077,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Plant Extracts|Quercetin,0,
"DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest",GO:0006977,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
DNA dealkylation involved in DNA repair,GO:0006307,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FTO
DNA double-strand break processing,GO:0000729,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
DNA duplex unwinding,GO:0032508,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
DNA endoreduplication,GO:0042023,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
DNA hypermethylation,GO:0044026,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bromodichloromethane|Cadmium Chloride|sodium arsenite|tributyltin,0,
DNA hypomethylation,GO:0044028,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Cadmium Chloride|Quercetin|S-Adenosylmethionine|sodium arsenite|Tetrachlorodibenzodioxin|tributyltin,0,
DNA integration,GO:0015074,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,EIF2AK1
DNA metabolic process,GO:0006259,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,alpha-naphthoflavone|Benzo(a)pyrene|Glucose|Plant Preparations|puerarin|Tobacco Smoke Pollution,0,
DNA methylation,GO:0006306,Non-alcoholic Fatty Liver Disease,MESH:D065626,21,"3,4,5,3',4'-pentachlorobiphenyl|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Choline|Copper|Folic Acid|Genistein|Glucose|Hydralazine|hydroquinone|Methionine|perfluorooctanoic acid|Quercetin|sodium arsenite|Sucrose|Tamoxifen|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution|Valproic Acid",0,
DNA methylation-dependent heterochromatin formation,GO:0006346,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SIRT1
DNA methylation involved in embryo development,GO:0043045,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Ethanol,0,
DNA methylation involved in gamete generation,GO:0043046,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|Cadmium|Cadmium Chloride",0,
DNA methylation on adenine,GO:0032775,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium Chloride,0,
DNA methylation on cytosine,GO:0032776,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Dietary Fats|Folic Acid|hydroquinone|sodium arsenite|Streptozocin,0,
DNA methylation on cytosine within a CG sequence,GO:0010424,Non-alcoholic Fatty Liver Disease,MESH:D065626,14,Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Choline|Folic Acid|hydroquinone|Methionine|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|sodium arsenite|Tobacco Smoke Pollution|Triclosan,0,
DNA modification,GO:0006304,Non-alcoholic Fatty Liver Disease,MESH:D065626,30,"4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Copper|Dietary Fats|Diethylnitrosamine|Dimethylnitrosamine|Dust|Folic Acid|Fructose|Genistein|geraniol|Glucose|Iron|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Plant Extracts|Quercetin|Reactive Oxygen Species|Resveratrol|S-Adenosylmethionine|Silymarin|sodium arsenite|Streptozocin|Tamoxifen|Tobacco Smoke Pollution|Triclosan|Valproic Acid",1,GSTT1
DNA recombination,GO:0006310,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RAG2
DNA repair,GO:0006281,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Arsenic Trioxide|Cadmium|Methionine|Resveratrol|sodium arsenite,0,
DNA repair-dependent chromatin remodeling,GO:0140861,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SIRT1
DNA replication,GO:0006260,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Raloxifene Hydrochloride|sodium arsenite,1,RDX
DNA synthesis involved in DNA repair,GO:0000731,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,1,SIRT1
DNA synthesis involved in DNA replication,GO:0090592,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Acetaminophen|Dietary Fats|perfluorooctanoic acid,0,
DNA synthesis involved in UV-damage excision repair,GO:1904161,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Acetaminophen,0,
DNA transport,GO:0051027,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,cyanoginosin LR|sodium arsenite,0,
dopamine biosynthetic process,GO:0042416,Non-alcoholic Fatty Liver Disease,MESH:D065626,13,Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Copper|Dietary Fats|Glucose|Maneb|Plant Extracts|Quercetin|Resveratrol|sodium arsenite|Streptozocin|Sulpiride,0,
dopamine biosynthetic process from tyrosine,GO:0006585,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|Taurine,0,
dopamine catabolic process,GO:0042420,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Sulpiride|Tamoxifen,0,
dopamine metabolic process,GO:0042417,Non-alcoholic Fatty Liver Disease,MESH:D065626,12,Acetaminophen|bisphenol A|Dabigatran|Ethanol|geraniol|Niacin|Plant Extracts|Quercetin|Resveratrol|sodium arsenite|Streptozocin|Valproic Acid,0,
dopaminergic neuron differentiation,GO:0071542,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Benzo(a)pyrene|bisphenol A|Copper|sodium arsenite|Tobacco Smoke Pollution,0,
dopamine secretion,GO:0014046,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Glucose|Iron,0,
"dopamine secretion, neurotransmission",GO:0061527,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
dopamine uptake,GO:0090494,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
"dorsal trunk growth, open tracheal system",GO:0035001,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
double-strand break repair via homologous recombination,GO:0000724,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,cyanoginosin LR|Valproic Acid,0,
drinking behavior,GO:0042756,Non-alcoholic Fatty Liver Disease,MESH:D065626,15,bisphenol A|Cadmium|Cadmium Chloride|Dietary Fats|Dietary Sugars|Diethylnitrosamine|Ethanol|Fructose|geraniol|perfluorooctanoic acid|Plant Extracts|Silymarin|sodium arsenite|Streptozocin|Valproic Acid,0,
D-serine biosynthetic process,GO:0070179,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
dTMP biosynthetic process,GO:0006231,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
ear development,GO:0043583,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Folic Acid,0,
eating behavior,GO:0042755,Non-alcoholic Fatty Liver Disease,MESH:D065626,14,Choline|Dietary Fats|Diethylnitrosamine|Ethanol|Fenofibrate|geraniol|Irinotecan|Maneb|Methionine|Plant Extracts|Silymarin|Streptozocin|Tamoxifen|Triclosan,3,ACE|CPT1A|LEP
ecdysone metabolic process,GO:0008205,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
ecdysone receptor-mediated signaling pathway,GO:0035076,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,1,NR1H4
eclosion,GO:0007562,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
ectopic germ cell programmed cell death,GO:0035234,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,IL1A|IL1B
eggshell formation,GO:0030703,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
elastin metabolic process,GO:0051541,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LEP
electron transport chain,GO:0022900,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Dietary Fats|geraniol|Silymarin|sodium arsenite|Thioctic Acid,0,
embryo development,GO:0009790,Non-alcoholic Fatty Liver Disease,MESH:D065626,17,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|cyanoginosin LR|Ethanol|Folic Acid|Glucose|GW 501516|perfluorohexanesulfonic acid|Resveratrol|Rosiglitazone|sodium arsenite|Triclosan|Valproic Acid,0,
embryo development ending in birth or egg hatching,GO:0009792,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Benzo(a)pyrene|bisphenol A|Cholesterol|Copper|Folic Acid|perfluorooctanoic acid|sodium arsenite,2,ACE|NR5A2
embryo implantation,GO:0007566,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,Benzo(a)pyrene|bisphenol A|cyanoginosin LR|Genistein|mancozeb|Quercetin|Resveratrol|sodium arsenite|Tetrachlorodibenzodioxin,4,IL1B|LIF|PPARD|STC2
embryonic body morphogenesis,GO:0010172,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Ethanol|perfluorooctanoic acid|sodium arsenite,0,
embryonic camera-type eye morphogenesis,GO:0048596,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
embryonic cleavage,GO:0040016,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Genistein|Resveratrol,1,NR5A2
embryonic digestive tract development,GO:0048566,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNF
embryonic digit morphogenesis,GO:0042733,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
embryonic eye morphogenesis,GO:0048048,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH1A1
embryonic forelimb morphogenesis,GO:0035115,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Caffeine,0,
embryonic heart tube elongation,GO:0036306,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
embryonic heart tube formation,GO:0003144,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
embryonic hemopoiesis,GO:0035162,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,1,IL3
embryonic hindlimb morphogenesis,GO:0035116,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Caffeine,0,
embryonic liver development,GO:1990402,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Methionine|perfluorooctanoic acid,1,TGFB1
embryonic morphogenesis,GO:0048598,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,alpha-naphthoflavone|Benzo(a)pyrene|Genistein|puerarin|Raloxifene Hydrochloride|Resveratrol,0,
embryonic organ development,GO:0048568,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Acetaminophen|Genistein|Rosiglitazone|Tamoxifen,0,
embryonic placenta development,GO:0001892,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Cadmium|Cadmium Chloride|perfluorooctanoic acid|tributyltin,1,CSF2
embryonic placenta morphogenesis,GO:0060669,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorohexanesulfonic acid,0,
embryonic skeletal system development,GO:0048706,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tetrachlorodibenzodioxin,0,
enamel mineralization,GO:0070166,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PPARA
endocannabinoid signaling pathway,GO:0071926,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
endochondral ossification,GO:0001958,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
endocrine pancreas development,GO:0031018,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SREBF1
endocytosis,GO:0006897,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Plant Extracts|Prednisolone,2,LDLR|VLDLR
endoderm development,GO:0007492,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
endonucleolytic cleavage involved in tRNA processing,GO:1905267,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
endoplasmic reticulum cisternal network maintenance,GO:0071785,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Tobacco Smoke Pollution|Tunicamycin,0,
endoplasmic reticulum organization,GO:0007029,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Arsenic Trioxide|Caffeine|Ethanol|Maneb|sodium arsenite|Taurine,0,
endoplasmic reticulum unfolded protein response,GO:0030968,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Benzo(a)pyrene|Tunicamycin,4,FGF21|NFE2L2|STC2|XBP1
endosomal lumen acidification,GO:0048388,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Iron,0,
endosome organization,GO:0007032,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
endothelial cell activation,GO:0042118,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Copper|Quercetin|Tunicamycin,0,
endothelial cell apoptotic process,GO:0072577,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,FGF21|TNF
endothelial cell chemotaxis,GO:0035767,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride",0,
endothelial cell chemotaxis to vascular endothelial growth factor,GO:0090668,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
endothelial cell-matrix adhesion,GO:0090673,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Resveratrol|sodium arsenite,0,
endothelial cell migration,GO:0043542,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
endothelial cell morphogenesis,GO:0001886,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
endothelial cell proliferation,GO:0001935,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,SCARB1|XBP1
endothelial microparticle formation,GO:0072565,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride",0,
endothelial to hematopoietic transition,GO:0098508,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
endothelial tube lumen extension,GO:0097498,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,alpha-naphthoflavone,0,
endothelial tube morphogenesis,GO:0061154,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
endothelin maturation,GO:0034959,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
energy derivation by oxidation of organic compounds,GO:0015980,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
energy homeostasis,GO:0097009,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,"3,4,5,3',4'-pentachlorobiphenyl|Dietary Fats|Resveratrol|sodium arsenite|Thioctic Acid",3,LEP|PPARD|SIRT1
energy reserve metabolic process,GO:0006112,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LEP
enteric nervous system development,GO:0048484,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
entrainment of circadian clock,GO:0009649,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium Chloride,0,
enzyme-linked receptor protein signaling pathway,GO:0007167,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
eosinophil extravasation,GO:0072682,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Resveratrol,0,
eosinophil homeostasis,GO:1990959,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,geraniol|perfluorooctanoic acid,0,
eosinophil migration,GO:0072677,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Cadmium|Cadmium Chloride,0,
epidermal growth factor receptor signaling pathway,GO:0007173,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|theaflavin-3,3'-digallate",0,
epidermis development,GO:0008544,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,PPARA|PPARD
epidermis morphogenesis,GO:0048730,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Caffeine,0,
epididymis development,GO:1905867,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,sodium arsenite|Streptozocin|Tamoxifen,0,
epigenetic regulation of gene expression,GO:0040029,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Arsenic Trioxide|bisphenol A|Cadmium|Dietary Fats|perfluorohexanesulfonic acid|perfluorooctanoic acid|sodium arsenite,0,
epinephrine metabolic process,GO:0042414,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
epithelial cell-cell adhesion,GO:0090136,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Arsenic Trioxide|bisphenol A|Resveratrol|sodium arsenite,0,
epithelial cell development,GO:0002064,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium Chloride|Sodium Glutamate,1,ESR1
epithelial cell differentiation,GO:0030855,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,CPT1A|GSTA1|PPARG
epithelial cell fate commitment,GO:0072148,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride",0,
"epithelial cell fate determination, open tracheal system",GO:0007425,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
epithelial cell maturation involved in salivary gland development,GO:0060691,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,XBP1
epithelial cell migration,GO:0010631,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
epithelial cell proliferation,GO:0050673,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,4,CSF2|PPARD|PPARG|TGFB1
epithelial cell proliferation involved in mammary gland duct elongation,GO:0060750,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ESR1
epithelial cell proliferation involved in salivary gland morphogenesis,GO:0060664,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNF
epithelial cilium movement involved in extracellular fluid movement,GO:0003351,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium Chloride|Tobacco Smoke Pollution,0,
epithelial fluid transport,GO:0042045,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,1,CSF2
epithelial structure maintenance,GO:0010669,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Benzo(a)pyrene|bisphenol A|Glucose|sodium arsenite|Tobacco Smoke Pollution,0,
epithelial to mesenchymal transition,GO:0001837,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Benzo(a)pyrene|bisphenol A|Glucose|Resveratrol|sodium arsenite|Tetrachlorodibenzodioxin,1,TGFB1
epithelial tube branching involved in lung morphogenesis,GO:0060441,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LAMA1
epithelial tube formation,GO:0072175,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
epithelium regeneration,GO:1990399,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Irinotecan,0,
epoxide metabolic process,GO:0097176,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Streptozocin,0,
epoxygenase P450 pathway,GO:0019373,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,CYP1A2|CYP2E1
ERAD pathway,GO:0036503,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,XBP1
ER-associated misfolded protein catabolic process,GO:0071712,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium Chloride,0,
ERBB2 signaling pathway,GO:0038128,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
ERK1 and ERK2 cascade,GO:0070371,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Plant Extracts|Reactive Oxygen Species|Resveratrol,0,
erythrocyte development,GO:0048821,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Niacin,0,
erythrocyte differentiation,GO:0030218,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Arsenic Trioxide|Folic Acid|hydroquinone|Quercetin|sodium arsenite,2,FGF21|JAK2
erythrocyte homeostasis,GO:0034101,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,"3,4,5,3',4'-pentachlorobiphenyl|Benzo(a)pyrene|bisphenol A|Cadmium|geraniol|Iron|Quercetin|sodium arsenite",0,
erythrocyte maturation,GO:0043249,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
erythropoietin-mediated signaling pathway,GO:0038162,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
establishment of blood-nerve barrier,GO:0008065,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
establishment of cell polarity,GO:0030010,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Diethylnitrosamine,0,
establishment of endothelial barrier,GO:0061028,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Blood Glucose|Glucose|perfluorooctanoic acid,1,RDX
establishment of endothelial blood-brain barrier,GO:0014045,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Valproic Acid,0,
establishment of endothelial intestinal barrier,GO:0090557,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Dextran Sulfate|Valproic Acid,0,
establishment of epithelial cell apical/basal polarity,GO:0045198,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LAMA1
establishment of epithelial cell apical/basal polarity involved in camera-type eye morphogenesis,GO:0003412,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LAMA1
establishment of localization in cell,GO:0051649,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,EIF2AK1|LDLR|MTTP|PRKCE
establishment of meiotic spindle localization,GO:0051295,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
establishment of mitotic spindle orientation,GO:0000132,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|Benzo(a)pyrene,0,
establishment of protein localization,GO:0045184,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,PRKCA|RDX
establishment of protein localization to plasma membrane,GO:0061951,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,gastrodin|Genistein|Pioglitazone|Quercetin|Resveratrol|Rosiglitazone,1,RDX
establishment of Sertoli cell barrier,GO:0097368,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Streptozocin,0,
establishment of skin barrier,GO:0061436,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,"Ethanol|Quercetin|Resveratrol|theaflavin-3,3'-digallate|Tobacco Smoke Pollution|Triclosan",0,
establishment of vesicle localization,GO:0051650,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IKBKG
estradiol secretion,GO:0035938,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|bisphenol A|Dietary Fats|Genistein|perfluorooctanoic acid|sodium arsenite|Tetrachlorodibenzodioxin|tributyltin",0,
estrogen biosynthetic process,GO:0006703,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,alpha-naphthoflavone|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|cyanoginosin LR|Dietary Fats|Genistein|sodium arsenite|Tetrachlorodibenzodioxin,0,
estrogen catabolic process,GO:0006711,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Genistein|Plant Extracts,0,
estrogen metabolic process,GO:0008210,Non-alcoholic Fatty Liver Disease,MESH:D065626,19,Acetaminophen|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium Chloride|Copper|cyanoginosin LR|Dextran Sulfate|Fructose|Genistein|Plant Extracts|Quercetin|Resveratrol|sodium arsenite|Streptozocin|Taurine|Tetrachlorodibenzodioxin|tributyltin|Tunicamycin,1,CYP1A2
estrogen secretion,GO:0035937,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Copper|Plant Extracts|Sodium Glutamate|tributyltin,0,
estrone secretion,GO:0035943,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,perfluorooctanoic acid|Tobacco Smoke Pollution,0,
estrous cycle,GO:0044849,Non-alcoholic Fatty Liver Disease,MESH:D065626,11,"Acetaminophen|bisphenol A|Caffeine|Niacinamide|Quercetin|Raloxifene Hydrochloride|sodium arsenite|Tamoxifen|Tetrachlorodibenzodioxin|theaflavin-3,3'-digallate|tributyltin",1,ALDH1A1
estrous cycle phase,GO:0060206,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Dietary Fats|Genistein|tributyltin,0,
estrus,GO:0060209,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Acetaminophen|bisphenol A|Dietary Fats|Genistein,0,
ethanolamine metabolic process,GO:0006580,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Benzo(a)pyrene|Choline|perfluorooctanoic acid,0,
ethanol catabolic process,GO:0006068,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,ALDH1B1|ALDH2
ethanol metabolic process,GO:0006067,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,2,ADH4|ALDH2
ether lipid biosynthetic process,GO:0008611,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Valproic Acid,0,
evoked excitatory postsynaptic potential,GO:0098817,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Caffeine,0,
excitatory postsynaptic potential,GO:0060079,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Sulpiride|Testosterone,0,
excretion,GO:0007588,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"Cadmium Chloride|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Quercetin|sodium arsenite",0,
exocrine pancreas development,GO:0031017,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,NR5A2|XBP1
exocytosis,GO:0006887,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Quercetin|sodium arsenite,0,
exosomal secretion,GO:1990182,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,perfluorooctanoic acid|sodium arsenite,0,
exploration behavior,GO:0035640,Non-alcoholic Fatty Liver Disease,MESH:D065626,17,"Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Dextran Sulfate|Ethanol|hydroquinone|mancozeb|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|obeticholic acid|Pioglitazone|Quercetin|Resveratrol|sodium arsenite|Streptozocin|tributyltin|Valproic Acid",0,
external genitalia morphogenesis,GO:0035261,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Caffeine,0,
extracellular exosome assembly,GO:0071971,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Acetaminophen,0,
extracellular exosome biogenesis,GO:0097734,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Acetaminophen,0,
extracellular matrix assembly,GO:0085029,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Dietary Fats|Silymarin|sodium arsenite|Streptozocin,1,TGFB1
extracellular matrix disassembly,GO:0022617,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
extracellular matrix organization,GO:0030198,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,puerarin|sodium arsenite,2,MMP1|TNF
extracellular vesicle biogenesis,GO:0140112,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Acetaminophen|Ethanol,0,
extrinsic apoptotic signaling pathway,GO:0097191,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,6,FAS|IL4|JAK2|TGFB1|TNF|TNFRSF1B
extrinsic apoptotic signaling pathway in absence of ligand,GO:0097192,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,5,FAS|IL1A|IL1B|IL3|IL4
extrinsic apoptotic signaling pathway via death domain receptors,GO:0008625,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Extracts,2,FAS|TNF
eye development,GO:0001654,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,2,LAMA1|RDX
eyelid development in camera-type eye,GO:0061029,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Valproic Acid,0,
eye morphogenesis,GO:0048592,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|perfluorooctanoic acid|sodium arsenite,0,
face morphogenesis,GO:0060325,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
fasciculation of motor neuron axon,GO:0097156,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
Fas signaling pathway,GO:0036337,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
fat cell differentiation,GO:0045444,Non-alcoholic Fatty Liver Disease,MESH:D065626,24,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|Cadmium|Cadmium Chloride|Dietary Fats|Dimethylnitrosamine|Genistein|Glucose|osteum|Palmitic Acid|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Pioglitazone|Quercetin|Reactive Oxygen Species|Resveratrol|Rosiglitazone|sodium arsenite|Tetrachlorodibenzodioxin|theaflavin-3,3'-digallate|tributyltin|Triglycerides",2,PPARG|SREBF1
fat cell proliferation,GO:0070341,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,bisphenol A|Cadmium|Cadmium Chloride|Dietary Fats|Dietary Sucrose|perfluorohexanesulfonic acid|perfluorooctanoic acid|Triclosan,1,PPARD
fat pad development,GO:0060613,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,bisphenol A|Dietary Fats|Ethanol|Olanzapine|perfluorohexanesulfonic acid|Resveratrol|Sodium Glutamate|Taurine|tectorigenin|Tetrachlorodibenzodioxin,0,
fatty acid beta-oxidation,GO:0006635,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,Benzo(a)pyrene|bisphenol A|Dietary Fats|Glucose|Olanzapine|Oleic Acid|Palmitic Acid|Resveratrol|Streptozocin,4,ADIPOQ|CPT1A|LEP|PPARD
fatty acid beta-oxidation using acyl-CoA oxidase,GO:0033540,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|perfluorooctanoic acid,0,
fatty acid biosynthetic process,GO:0006633,Non-alcoholic Fatty Liver Disease,MESH:D065626,14,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|aroclor 1260|Benzo(a)pyrene|bisphenol A|Dietary Fats|Ethanol|Fenofibrate|Fructose|Olive Oil|Palmitic Acid|Plant Extracts|Resveratrol|Streptozocin",1,XBP1
fatty acid catabolic process,GO:0009062,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Glucose|Sodium Glutamate,2,LEP|PPARD
fatty acid derivative biosynthetic process,GO:1901570,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Resveratrol,0,
fatty acid derivative metabolic process,GO:1901568,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Dietary Fats|Taurine,0,
"fatty acid elongation, unsaturated fatty acid",GO:0019368,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
fatty acid homeostasis,GO:0055089,Non-alcoholic Fatty Liver Disease,MESH:D065626,19,"5-(3-methoxy-5-(4-methoxystyryl)phenoxy)-2,2-dimethylpentanoic acid|7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid|bisphenol A|Cadmium|Cholesterol, Dietary|Choline|Dietary Fats|Dietary Sucrose|geraniol|Linoleic Acid|Methionine|obeticholic acid|Oleic Acid|Palmitic Acid|Plant Extracts|Resveratrol|sodium arsenite|Streptozocin|Sulpiride",4,INS|NR1H4|SIRT1|XBP1
fatty acid metabolic process,GO:0006631,Non-alcoholic Fatty Liver Disease,MESH:D065626,29,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|aroclor 1260|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Choline|Dietary Fats|Dietary Sucrose|Dietary Sugars|Ethanol|Fatty Acids, Omega-3|Folic Acid|Fructose|Linoleic Acid|Methionine|Oleic Acid|Olive Oil|Palmitic Acid|Palm Oil|perfluorooctanoic acid|Resveratrol|Rosiglitazone|sodium arsenite|Streptozocin|Taurine|Thioctic Acid|Triclosan",5,CPT1A|CYP2E1|PPARA|PPARD|PPARG
fatty acid omega-oxidation,GO:0010430,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ADH4
fatty acid oxidation,GO:0019395,Non-alcoholic Fatty Liver Disease,MESH:D065626,14,Acetaminophen|Allopurinol|Bezafibrate|Dietary Fats|Fenofibrate|Glucose|Linoleic Acid|Olanzapine|Oleic Acid|Palmitic Acid|pirinixic acid|Resveratrol|Rosiglitazone|Tunicamycin,3,ADIPOQ|PPARD|PPARG
fatty acid transport,GO:0015908,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,bisphenol A|Niacin|Oleic Acid|Palmitic Acid|pirinixic acid|Resveratrol|Rosiglitazone,1,PPARD
Fc-epsilon receptor signaling pathway,GO:0038095,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
Fc-gamma receptor signaling pathway involved in phagocytosis,GO:0038096,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Iron,2,PRKCD|PRKCE
fear response,GO:0042596,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Folic Acid,0,
feeding behavior,GO:0007631,Non-alcoholic Fatty Liver Disease,MESH:D065626,21,aroclor 1260|bisphenol A|Butter|Cadmium|Cadmium Chloride|Dextran Sulfate|Dietary Fats|Diethylnitrosamine|Ethanol|Fructose|Margarine|Olive Oil|Quercetin|Rosiglitazone|sodium arsenite|Sodium Glutamate|Streptozocin|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Valproic Acid,0,
female genitalia morphogenesis,GO:0048807,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Caffeine,0,
female germ-line cyst formation,GO:0048135,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Acetaminophen,0,
female gonad development,GO:0008585,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|sodium arsenite|Tamoxifen|Tetrachlorodibenzodioxin,0,
female gonad morphogenesis,GO:0061040,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,0,
female mating behavior,GO:0060180,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Triclosan,0,
female meiosis I,GO:0007144,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
female meiosis II,GO:0007147,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
female pregnancy,GO:0007565,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Caffeine|Tamoxifen|Tetrachlorodibenzodioxin,7,ABCC2|ACE|AHR|IL1RN|IL4|LEP|TGFB1
female sex determination,GO:0030237,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP17A1
ferroptosis,GO:0097707,Non-alcoholic Fatty Liver Disease,MESH:D065626,13,Acetaminophen|Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Ethanol|Glucose|Iron|Maneb|Palmitic Acid|Quercetin|Resveratrol|sodium arsenite,0,
fertilization,GO:0009566,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Acetaminophen|bisphenol A|Copper|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution,0,
fetal process involved in parturition,GO:0060138,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
fever generation,GO:0001660,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,IL1A|IL1B|IL1RN
fibrinolysis,GO:0042730,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,F2|SERPINB2
fibroblast activation,GO:0072537,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Folic Acid,0,
fibroblast growth factor receptor signaling pathway,GO:0008543,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,FGF21|KLB
fibroblast migration,GO:0010761,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Resveratrol,0,
fibroblast proliferation,GO:0048144,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,ESR1|LIF
filopodium assembly,GO:0046847,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
fin development,GO:0033333,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR2
fin regeneration,GO:0031101,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,IL1B|SIRT1
flagellated sperm motility,GO:0030317,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,aroclor 1260|bisphenol A|Plant Extracts|Quercetin|Thioctic Acid,0,
flavonoid metabolic process,GO:0009812,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Genistein,0,
flight behavior,GO:0007629,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Eucalyptol,0,
fluoride export across plasma membrane,GO:0140116,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"theaflavin-3,3'-digallate",0,
foam cell differentiation,GO:0090077,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cholesterol|Resveratrol,0,
focal adhesion assembly,GO:0048041,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|sodium arsenite,0,
folate import across plasma membrane,GO:1904447,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Valproic Acid,0,
folic acid metabolic process,GO:0046655,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Dietary Fats|Folic Acid|sodium arsenite,0,
folic acid transport,GO:0015884,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium Chloride|Folic Acid,1,FOLR2
follicle cell of egg chamber development,GO:0030707,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
follicle-stimulating hormone secretion,GO:0046884,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|sodium arsenite,0,
follicular B cell differentiation,GO:0002316,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
follicular fluid formation in ovarian follicle antrum,GO:0001548,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
forebrain development,GO:0030900,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Choline|Ethanol|Folic Acid,1,MRTFA
forebrain morphogenesis,GO:0048853,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
formaldehyde catabolic process,GO:0046294,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ADH4
formation of peptidyl-cystine persulfide by sulphur transfer from H2S,GO:0044527,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
frontal suture morphogenesis,GO:0060364,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
fructosamine biosynthetic process,GO:0030391,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Dietary Fats|Quercetin|Resveratrol|Sodium Glutamate|Sucrose,0,
fructosamine catabolic process,GO:0030392,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH1A1
fructose biosynthetic process,GO:0046370,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Fructose|Glucose|Streptozocin,0,
fructose catabolic process,GO:0006001,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH1A1
fructose metabolic process,GO:0006000,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Fructose,0,
fucose biosynthetic process,GO:0042353,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Diethylnitrosamine,0,
fucose metabolic process,GO:0006004,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Streptozocin,0,
fucosylation,GO:0036065,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
fumarate metabolic process,GO:0006106,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tamoxifen,0,
fused antrum stage,GO:0048165,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"3,4,5,3',4'-pentachlorobiphenyl",0,
fusion of sperm to egg plasma membrane involved in single fertilization,GO:0007342,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FOLR2
G0 to G1 transition,GO:0045023,Non-alcoholic Fatty Liver Disease,MESH:D065626,22,"Acetaminophen|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Copper|cyanoginosin LR|Diethylnitrosamine|Folic Acid|Fructose|Genistein|Glucose|hydroquinone|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|perfluorooctanoic acid|Plant Extracts|Quercetin|Resveratrol|sodium arsenite|Tamoxifen",0,
G1/S transition of mitotic cell cycle,GO:0000082,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
G2/M transition of mitotic cell cycle,GO:0000086,Non-alcoholic Fatty Liver Disease,MESH:D065626,22,"Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Copper|cyanoginosin LR|Diethylnitrosamine|Folic Acid|Fructose|Genistein|Glucose|hydroquinone|Irinotecan|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|perfluorooctanoic acid|Plant Extracts|Quercetin|Resveratrol|sodium arsenite|Tamoxifen",0,
galactose biosynthetic process,GO:0046369,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
galactose metabolic process,GO:0006012,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Ethanol|Resveratrol,0,
gamma-aminobutyric acid biosynthetic process,GO:0009449,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,gastrodin|Plant Preparations,1,ALDH1A1
gamma-aminobutyric acid import,GO:0051939,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Sodium Glutamate,0,
gamma-aminobutyric acid metabolic process,GO:0009448,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Dextran Sulfate|Dietary Fats|Dietary Sugars|Glucose|Plant Extracts|Streptozocin|Valproic Acid,0,
gamma-aminobutyric acid signaling pathway,GO:0007214,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Ethanol,0,
ganglion development,GO:0061548,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
gap junction assembly,GO:0016264,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
gap junction-mediated intercellular transport,GO:1990349,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Resveratrol|Thioctic Acid|Triclosan,0,
GDP-mannose metabolic process,GO:0019673,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
GDP metabolic process,GO:0046710,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
gene expression,GO:0010467,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Benzo(a)pyrene|bisphenol A|Cadmium|Chromium|sodium arsenite|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution,6,ADIPOQ|FAS|LIF|PPARA|PTEN|TGFB1
generation of neurons,GO:0048699,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
generation of precursor metabolites and energy,GO:0006091,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,ADIPOQ|ATP5F1B|PPARD
genomic imprinting,GO:0071514,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
germ cell development,GO:0007281,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Acetaminophen|bisphenol A|Tetrachlorodibenzodioxin,0,
germ cell migration,GO:0008354,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,1,TGFB1
ghrelin secretion,GO:0036321,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
gland development,GO:0048732,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR
glandular epithelial cell differentiation,GO:0002067,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
glandular epithelial cell maturation,GO:0002071,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,XBP1
glial cell activation,GO:0061900,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,geraniol|Sodium Glutamate,0,
glial cell-derived neurotrophic factor receptor signaling pathway,GO:0035860,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
glial cell differentiation,GO:0010001,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
glial cell-neuron signaling,GO:0150098,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNFRSF1B
glial cell proliferation,GO:0014009,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|Sodium Glutamate,0,
glomerular basement membrane development,GO:0032836,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Caffeine|Dietary Fats|Streptozocin,0,
glomerular filtration,GO:0003094,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Acetaminophen|Cadmium|Carvedilol|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Streptozocin,0,
glomerulus morphogenesis,GO:0072102,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR
glucagon secretion,GO:0070091,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,"bisphenol A|Cadmium Chloride|Cholesterol, Dietary|Glucose|perfluorooctanoic acid|Streptozocin|Triclosan",0,
glucocorticoid biosynthetic process,GO:0006704,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP17A1
glucocorticoid metabolic process,GO:0008211,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
gluconeogenesis,GO:0006094,Non-alcoholic Fatty Liver Disease,MESH:D065626,21,"3,4,5,3',4'-pentachlorobiphenyl|4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid|Arsenic Trioxide|bisphenol A|Blood Glucose|Cadmium Chloride|Dietary Fats|Dietary Sucrose|Ethanol|Fructose|Glucose|GW 4064|Palmitic Acid|perfluorooctanoic acid|Quercetin|Resveratrol|Rosiglitazone|Sodium Glutamate|Streptozocin|Sucrose|Tamoxifen",1,PPARA
glucose 6-phosphate metabolic process,GO:0051156,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Glucose|perfluorooctanoic acid,0,
glucose catabolic process,GO:0006007,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Dietary Fats|Glucose|Resveratrol,0,
glucose catabolic process to lactate,GO:0019659,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
glucose homeostasis,GO:0042593,Non-alcoholic Fatty Liver Disease,MESH:D065626,41,"3,4,5,3',4'-pentachlorobiphenyl|5-(3-methoxy-5-(4-methoxystyryl)phenoxy)-2,2-dimethylpentanoic acid|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Blood Glucose|Cadmium|Cadmium Chloride|Choline|cobaltiprotoporphyrin|cyanoginosin LR|Dietary Carbohydrates|Dietary Fats|Diethylnitrosamine|Ethanol|Fatty Acids, Omega-3|Folic Acid|Fructose|geraniol|Glucocorticoids|Glucose|gypenoside LXXV|Methionine|Niacinamide|obeticholic acid|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Plant Extracts|Plant Preparations|Quercetin|Resveratrol|Rosiglitazone|sodium arsenite|Streptozocin|Sulpiride|Taurine|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution|tributyltin|Triclosan",6,ADIPOQ|INS|LEP|NR1H4|PDK4|PPARG
glucose import,GO:0046323,Non-alcoholic Fatty Liver Disease,MESH:D065626,16,Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Glucose|Palmitates|Palmitic Acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Quercetin|Rosiglitazone|sodium arsenite|Streptozocin|Taurine|Valproic Acid,0,
glucose import across plasma membrane,GO:0098708,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Glucose|Resveratrol|Rosiglitazone,0,
glucose import in response to insulin stimulus,GO:0044381,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Glucose|Palmitic Acid|Pioglitazone,0,
glucose metabolic process,GO:0006006,Non-alcoholic Fatty Liver Disease,MESH:D065626,28,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|Benzo(a)pyrene|bisphenol A|Blood Glucose|Cadmium|cyanoginosin LR|Dietary Fats|Ethanol|Folic Acid|Glucose|gypenoside LXXV|mancozeb|Oleic Acid|Palmitates|Palmitic Acid|Palm Oil|perfluorooctanoic acid|Pioglitazone|Resveratrol|sodium arsenite|Sodium Glutamate|Streptozocin|Tetrachlorodibenzodioxin|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Triclosan",7,ADIPOQ|CPT1A|INS|LEP|PPARA|PPARD|TNF
glucose transmembrane transport,GO:1904659,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,bisphenol A|Cadmium|Cadmium Chloride|Dietary Fats|Glucose|Plant Extracts|Quercetin,1,PPARD
glucosylceramide biosynthetic process,GO:0006679,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
glucosylceramide metabolic process,GO:0006678,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
glutamate biosynthetic process,GO:0006537,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,"Arsenic Trioxide|bisphenol A|gastrodin|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|perfluorooctanoic acid|Streptozocin|Tobacco Smoke Pollution",0,
glutamate catabolic process,GO:0006538,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
glutamate metabolic process,GO:0006536,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|Caffeine|Ethanol|Genistein|perfluorooctanoic acid|Valproic Acid,0,
glutamate secretion,GO:0014047,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
glutamine biosynthetic process,GO:0006542,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Acetaminophen|bisphenol A|Dietary Fats|Irinotecan|perfluorooctanoic acid,0,
glutamine metabolic process,GO:0006541,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Dextran Sulfate|sodium arsenite|Thioctic Acid,0,
glutathione biosynthetic process,GO:0006750,Non-alcoholic Fatty Liver Disease,MESH:D065626,54,"4-hydroxy-2-nonenal|Acetaminophen|alisol B|alpha-naphthoflavone|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Carvedilol|Cholesterol|Chromium|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Carbohydrates|Dietary Fats|Diethylnitrosamine|Dimethylnitrosamine|Ethanol|Fatty Acids, Omega-3|Folic Acid|Fructose|Genistein|geraniol|Glucose|Irinotecan|Iron|mancozeb|Maneb|Methionine|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Orlistat|Palmitic Acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Plant Preparations|Quercetin|Resveratrol|Rosiglitazone|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Taurine|Testosterone|Tetrachlorodibenzodioxin|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Valproic Acid",0,
glutathione catabolic process,GO:0006751,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,alisol B|bisphenol A|Cadmium Chloride|Dietary Fats|Fructose|sodium arsenite|Thioctic Acid|Tobacco Smoke Pollution,0,
glutathione derivative biosynthetic process,GO:1901687,Non-alcoholic Fatty Liver Disease,MESH:D065626,20,Acetaminophen|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium Chloride|Choline|Copper|Diethylnitrosamine|Ethanol|Genistein|geraniol|Glucose|Methionine|Plant Extracts|Quercetin|Resveratrol|Rosiglitazone|sodium arsenite|Streptozocin|tributyltin,3,GSTA1|GSTM1|GSTP1
glutathione metabolic process,GO:0006749,Non-alcoholic Fatty Liver Disease,MESH:D065626,65,"Acetaminophen|aroclor 1260|Arsenic Trioxide|Benzo(a)pyrene|Bezafibrate|bisphenol A|Blood Glucose|Cadmium|Cadmium Chloride|Caffeine|Carvedilol|Cholesterol|Cholesterol, Dietary|Choline|cobaltiprotoporphyrin|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Fats|Dietary Sucrose|Diethylnitrosamine|Dimethylnitrosamine|Ethanol|Fatty Acids, Omega-3|Fenofibrate|Folic Acid|Fructose|gastrodin|Genistein|geraniol|Glucose|hugan qingzhi|hydroquinone|Iron|Linoleic Acid|Lipids|mancozeb|Maneb|Methionine|Niacin|Niacinamide|obeticholic acid|Oleic Acid|Palmitic Acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Plant Preparations|puerarin|Quercetin|Reactive Oxygen Species|Resveratrol|Rosiglitazone|S-Adenosylmethionine|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Tamoxifen|Taurine|Testosterone|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Valproic Acid",4,GSTA1|GSTM1|GSTP1|GSTT1
glutathione transmembrane transport,GO:0034775,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
glutathione transport,GO:0034635,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
glyceraldehyde-3-phosphate biosynthetic process,GO:0046166,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
glyceraldehyde-3-phosphate metabolic process,GO:0019682,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
glycerol-3-phosphate biosynthetic process,GO:0046167,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
glycerol-3-phosphate metabolic process,GO:0006072,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Glucose,0,
glycerol biosynthetic process,GO:0006114,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Glucose|Sodium Glutamate,1,LEP
glycerol biosynthetic process from pyruvate,GO:0046327,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
glycerolipid metabolic process,GO:0046486,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorohexanesulfonic acid,0,
glycerol metabolic process,GO:0006071,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Palmitic Acid|Rosiglitazone,0,
glycerol transmembrane transport,GO:0015793,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Caffeine|Glucose|Plant Extracts,0,
glycerophospholipid biosynthetic process,GO:0046474,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
glycerophospholipid metabolic process,GO:0006650,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,"Cadmium Chloride|Dietary Carbohydrates|Dietary Fats|Fatty Acids, Omega-3|Folic Acid|perfluorohexanesulfonic acid",2,PEMT|PNPLA3
glycine biosynthetic process,GO:0006545,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Acetaminophen|bisphenol A|sodium arsenite|Tobacco Smoke Pollution,0,
glycine metabolic process,GO:0006544,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Cadmium|Cadmium Chloride|Palmitic Acid|perfluorooctanoic acid,1,GNMT
glycogen biosynthetic process,GO:0005978,Non-alcoholic Fatty Liver Disease,MESH:D065626,13,Arsenic Trioxide|Cadmium Chloride|Choline|Dietary Fats|Folic Acid|Glucose|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Quercetin|Rosiglitazone|Streptozocin|Taurine,0,
glycogen catabolic process,GO:0005980,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Acetaminophen|Caffeine|Dietary Fats|Fructose,0,
glycogen metabolic process,GO:0005977,Non-alcoholic Fatty Liver Disease,MESH:D065626,13,"3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|Cadmium|Cholesterol|Dietary Fats|Fructose|Niacinamide|Palmitates|Plant Extracts|Quercetin|sodium arsenite|Streptozocin|tributyltin",1,GNMT
glycolate metabolic process,GO:0009441,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
glycolipid metabolic process,GO:0006664,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Bile Acids and Salts|Cholesterol|Choline|Glucose|Lipids|Triglycerides,0,
glycolytic process,GO:0006096,Non-alcoholic Fatty Liver Disease,MESH:D065626,11,bisphenol A|Cadmium|Cadmium Chloride|Dietary Fats|Glucose|Methionine|Niacin|Palmitic Acid|Rosiglitazone|sodium arsenite|Tamoxifen,0,
glycolytic process through glucose-6-phosphate,GO:0061620,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
glycoprotein biosynthetic process,GO:0009101,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Diethylnitrosamine|Ethanol,0,
glycoprotein metabolic process,GO:0009100,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Streptozocin|Valproic Acid,0,
glycoprotein transport,GO:0034436,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,VLDLR
glycosaminoglycan biosynthetic process,GO:0006024,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,B3GAT1
glycosaminoglycan metabolic process,GO:0030203,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,0,
glycoside metabolic process,GO:0016137,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
glycoside transport,GO:1901656,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
glycosylation,GO:0070085,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Glucose|Streptozocin,0,
GMP biosynthetic process,GO:0006177,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
Golgi organization,GO:0007030,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Maneb|Taurine,0,
GPI anchor biosynthetic process,GO:0006506,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
G protein-coupled acetylcholine receptor signaling pathway,GO:0007213,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|sodium arsenite,0,
G protein-coupled receptor signaling pathway,GO:0007186,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,7,ALDH4A1|ESR1|F2|INS|JAK2|PPARD|PPARG
granulocyte activation,GO:0036230,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Reactive Oxygen Species,0,
granulocyte differentiation,GO:0030851,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,"3,4,5,3',4'-pentachlorobiphenyl|Arsenic Trioxide",0,
granulocyte-macrophage colony-stimulating factor signaling pathway,GO:0038157,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,CSF2|JAK2
granuloma formation,GO:0002432,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
granzyme-mediated programmed cell death signaling pathway,GO:0140507,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRF1
gravitaxis,GO:0042332,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,sodium arsenite|Taurine,0,
grooming behavior,GO:0007625,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|Cadmium|Ethanol|Pioglitazone|Taurine|Valproic Acid,0,
growth,GO:0040007,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Benzo(a)pyrene|bisphenol A|Cadmium|Copper|sodium arsenite,0,
growth hormone receptor signaling pathway,GO:0060396,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
growth hormone receptor signaling pathway via JAK-STAT,GO:0060397,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,1,JAK2
growth involved in heart morphogenesis,GO:0003241,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
growth plate cartilage chondrocyte development,GO:0003431,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
GTP metabolic process,GO:0046039,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
guanine biosynthetic process,GO:0046099,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
guanine metabolic process,GO:0046098,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dextran Sulfate|perfluorooctanoic acid,0,
guanosine biosynthetic process,GO:0046114,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
habituation,GO:0046959,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Acetaminophen|bisphenol A,0,
halogenated hydrocarbon metabolic process,GO:0042197,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP2E1
hatching,GO:0035188,Non-alcoholic Fatty Liver Disease,MESH:D065626,16,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|alpha-naphthoflavone|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|cyanoginosin LR|Folic Acid|Genistein|Plant Extracts|sodium arsenite|Tamoxifen|Tobacco Smoke Pollution|Triclosan|Valproic Acid,1,XBP1
hatching gland development,GO:0048785,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,XBP1
head development,GO:0060322,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Benzo(a)pyrene|bisphenol A|Ethanol|sodium arsenite|Triclosan|Valproic Acid,0,
head morphogenesis,GO:0060323,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Ethanol,0,
heart capillary growth,GO:0003248,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Fenofibrate,0,
heart contraction,GO:0060047,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|bisphenol A|Cadmium|Caffeine|Copper|geraniol|Rosiglitazone|Tamoxifen|Triclosan,1,ACE
heart development,GO:0007507,Non-alcoholic Fatty Liver Disease,MESH:D065626,11,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|Benzo(a)pyrene|bisphenol A|Cadmium|Caffeine|Copper|Ethanol|Folic Acid|Genistein|Resveratrol|sodium arsenite,8,FTO|IL1A|PPARA|PPARD|PPARG|PTEN|TGFB1|VLDLR
heart formation,GO:0060914,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Folic Acid|Triclosan,0,
heart growth,GO:0060419,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
heart looping,GO:0001947,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Tetrachlorodibenzodioxin,1,TRIB3
heart morphogenesis,GO:0003007,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,1,CAT
heart process,GO:0003015,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Streptozocin,0,
heart valve morphogenesis,GO:0003179,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
heat acclimation,GO:0010286,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
hematopoietic or lymphoid organ development,GO:0048534,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RAG2
hematopoietic progenitor cell differentiation,GO:0002244,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,2,IL3|TGFB1
hematopoietic stem cell differentiation,GO:0060218,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Cadmium Chloride|Resveratrol,1,ACE
heme biosynthetic process,GO:0006783,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
heme catabolic process,GO:0042167,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Cadmium Chloride|carnosol|cobaltiprotoporphyrin|Tetrachlorodibenzodioxin,1,ABCC2
heme metabolic process,GO:0042168,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Diethylnitrosamine|Iron,0,
hemoglobin biosynthetic process,GO:0042541,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,Ethanol|Eucalyptol|Folic Acid|hydroquinone|Plant Extracts|S-Adenosylhomocysteine|S-Adenosylmethionine|sodium arsenite|Tetrachlorodibenzodioxin,0,
hemoglobin catabolic process,GO:0042540,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
hemoglobin metabolic process,GO:0020027,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|Folic Acid|Iron|sodium arsenite|Streptozocin|Tobacco Smoke Pollution,1,CAT
hemopoiesis,GO:0030097,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Cadmium|cyanoginosin LR|Resveratrol|sodium arsenite,2,IL3|JAK2
hepaticobiliary system development,GO:0061008,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Methionine,0,
hepaticobiliary system process,GO:0061007,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
hepatic stellate cell activation,GO:0035733,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,"Cholesterol, Dietary|Dietary Fats|Dietary Sucrose|Ethanol|Fructose|gypenoside LXXV|sodium arsenite|Valproic Acid",0,
hepatic stellate cell proliferation,GO:1990922,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
hepatoblast differentiation,GO:0061017,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NR5A2
hepatocyte apoptotic process,GO:0097284,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
hepatocyte differentiation,GO:0070365,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Niacinamide|Quercetin,0,
hepatocyte homeostasis,GO:0036333,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Acetaminophen|Folic Acid,0,
hepoxilin biosynthetic process,GO:0051122,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,GSTM1|GSTP1
heterochromatin formation,GO:0031507,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,1,SIRT1
heterocycle metabolic process,GO:0046483,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Benzo(a)pyrene|Dextran Sulfate|Ethanol|Niacin|Niacinamide|perfluorooctanoic acid|sodium arsenite,0,
heterotypic cell-cell adhesion,GO:0034113,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|Benzo(a)pyrene|mancozeb,0,
hexachlorocyclohexane metabolic process,GO:0019497,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,0,
hexitol metabolic process,GO:0006059,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Benzo(a)pyrene,0,
hexokinase-dependent signaling,GO:0009747,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Taurine,0,
hexose biosynthetic process,GO:0019319,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Diethylnitrosamine|Taurine,0,
hexose metabolic process,GO:0019318,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Fructose|Streptozocin,0,
hexose transmembrane transport,GO:0008645,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
high-density lipoprotein particle assembly,GO:0034380,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRKACA
high-density lipoprotein particle clearance,GO:0034384,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Ethanol,2,LDLR|SCARB1
high-density lipoprotein particle remodeling,GO:0034375,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SCARB1
hindbrain development,GO:0030902,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Folic Acid,0,
hippocampus development,GO:0021766,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Choline|Ethanol,1,CYP17A1
histamine biosynthetic process,GO:0001694,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
histamine secretion,GO:0001821,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,bisphenol A|Dietary Fats|perfluorooctanoic acid|Plant Extracts|Plant Preparations|Quercetin|Resveratrol|Streptozocin,1,CSF2
histamine secretion by mast cell,GO:0002553,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,perfluorooctanoic acid|Plant Extracts|Quercetin,0,
histamine secretion involved in inflammatory response,GO:0002441,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,geraniol,0,
histamine secretion mediated by immunoglobulin,GO:0097280,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Dextran Sulfate|Ethanol|Glucose|Prednisolone|Quercetin|Sulpiride,0,
histidine biosynthetic process,GO:0000105,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,perfluorooctanoic acid|sodium arsenite,0,
histidine metabolic process,GO:0006547,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,0,
histone acetylation,GO:0016573,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
histone H2A ubiquitination,GO:0033522,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Benzo(a)pyrene|sodium arsenite,0,
histone H2B conserved C-terminal lysine ubiquitination,GO:0071894,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Streptozocin,0,
histone H3 acetylation,GO:0043966,Non-alcoholic Fatty Liver Disease,MESH:D065626,16,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|Arsenic Trioxide|bisphenol A|Cadmium Chloride|Dietary Fats|Genistein|Glucose|hydroquinone|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Quercetin|Resveratrol|sodium arsenite|Streptozocin|Tobacco Smoke Pollution|Valproic Acid",0,
histone H3 deacetylation,GO:0070932,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Valproic Acid,0,
histone H3-K14 acetylation,GO:0044154,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Caffeine|Resveratrol|sodium arsenite,0,
histone H3-K18 acetylation,GO:0043971,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Dietary Fats|hydroquinone|sodium arsenite,0,
histone H3-K23 acetylation,GO:0043972,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
histone H3-K27 acetylation,GO:0043974,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Caffeine|Ethanol|Resveratrol|sodium arsenite,0,
histone H3-K27 trimethylation,GO:0098532,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,"Acetaminophen|Benzo(a)pyrene|bisphenol A|Dietary Fats|Diethylnitrosamine|Methionine|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Resveratrol|sodium arsenite|Tobacco Smoke Pollution",0,
histone H3-K36 dimethylation,GO:0097676,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Dietary Fats|Diethylnitrosamine|Ethanol|Methionine,0,
histone H3-K36 methylation,GO:0010452,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Ethanol,0,
histone H3-K36 trimethylation,GO:0097198,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|Diethylnitrosamine|Ethanol|Methionine|Reactive Oxygen Species|sodium arsenite,0,
histone H3-K4 acetylation,GO:0043973,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Genistein,0,
histone H3-K4 demethylation,GO:0034720,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
histone H3-K4 dimethylation,GO:0044648,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Benzo(a)pyrene|bisphenol A|Ethanol|Folic Acid|Glucose|Iron|sodium arsenite,0,
histone H3-K4 methylation,GO:0051568,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Ethanol|Glucose|sodium arsenite,0,
histone H3-K4 monomethylation,GO:0097692,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Glucose|sodium arsenite|Streptozocin,0,
histone H3-K4 trimethylation,GO:0080182,Non-alcoholic Fatty Liver Disease,MESH:D065626,11,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|bisphenol A|Cadmium|Ethanol|Glucose|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|perfluorooctanoic acid|sodium arsenite|Streptozocin|Tobacco Smoke Pollution",0,
histone H3-K56 acetylation,GO:0097043,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Ethanol|Niacinamide|Tetrachlorodibenzodioxin,0,
histone H3-K9 acetylation,GO:0043970,Non-alcoholic Fatty Liver Disease,MESH:D065626,13,Acetaminophen|bisphenol A|Caffeine|Ethanol|Genistein|Hydralazine|hydroquinone|Niacinamide|Plant Extracts|Resveratrol|sodium arsenite|Streptozocin|Tetrachlorodibenzodioxin,0,
histone H3-K9 demethylation,GO:0033169,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Quercetin|sodium arsenite,0,
histone H3-K9 dimethylation,GO:0036123,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,Benzo(a)pyrene|bisphenol A|Cadmium|Copper|Ethanol|Folic Acid|Iron|perfluorooctanoic acid|Reactive Oxygen Species|sodium arsenite,0,
histone H3-K9 methylation,GO:0051567,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Glucose|sodium arsenite,0,
histone H3-K9 trimethylation,GO:0036124,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|Ethanol|sodium arsenite",0,
histone H4 acetylation,GO:0043967,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,"2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|Arsenic Trioxide|bisphenol A|Cadmium Chloride|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Quercetin|Valproic Acid",0,
histone H4 deacetylation,GO:0070933,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Valproic Acid,0,
histone H4-K12 acetylation,GO:0043983,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Cadmium|Cadmium Chloride|sodium arsenite,0,
histone H4-K16 acetylation,GO:0043984,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Ethanol|sodium arsenite|Tobacco Smoke Pollution,0,
histone H4-K16 deacetylation,GO:1990678,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Streptozocin,0,
histone H4-K20 trimethylation,GO:0034773,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Ethanol|sodium arsenite|Tobacco Smoke Pollution,0,
histone H4-K5 acetylation,GO:0043981,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium Chloride|sodium arsenite,0,
histone H4-K8 acetylation,GO:0043982,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
histone methylation,GO:0016571,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
homeostasis of number of cells,GO:0048872,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Valproic Acid,0,
homeostasis of number of cells within a tissue,GO:0048873,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"bisphenol A|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Tetrachlorodibenzodioxin",0,
homeostatic process,GO:0042592,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NR5A2
homocysteine biosynthetic process,GO:0071268,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|sodium arsenite,0,
homocysteine metabolic process,GO:0050667,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,bisphenol A|Choline|Dietary Fats|Folic Acid|geraniol|Methionine|sodium arsenite,0,
homologous chromosome orientation involved in meiotic metaphase I plate congression,GO:0031619,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
homologous chromosome pairing at meiosis,GO:0007129,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
homotypic cell-cell adhesion,GO:0034109,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,4-hydroxy-2-nonenal|bisphenol A|perfluorooctanoic acid|sodium arsenite,0,
hormone biosynthetic process,GO:0042446,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,CYP17A1|CYP1A2
hormone catabolic process,GO:0042447,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ACE
hormone-mediated signaling pathway,GO:0009755,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,5,JAK2|NR5A2|PPARA|PPARD|PPARG
hormone metabolic process,GO:0042445,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,2,ACE|LEP
host-mediated regulation of intestinal microbiota composition,GO:0048874,Non-alcoholic Fatty Liver Disease,MESH:D065626,12,Arsenic Trioxide|Bile Acids and Salts|bisphenol A|Cadmium|Dietary Fats|Ethanol|obeticholic acid|sodium arsenite|Sodium Glutamate|Streptozocin|tectorigenin|Triclosan,0,
HRI-mediated signaling,GO:0140468,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,EIF2AK1
humoral immune response,GO:0006959,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNF
humoral immune response mediated by circulating immunoglobulin,GO:0002455,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"Fatty Acids, Omega-3|perfluorohexanesulfonic acid|perfluorooctanoic acid",0,
hyaluronan biosynthetic process,GO:0030213,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL1B
hyaluronan catabolic process,GO:0030214,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
hyaluronan metabolic process,GO:0030212,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
hydrocarbon metabolic process,GO:0120252,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Benzo(a)pyrene|sodium arsenite|Taurine,0,
hydrogen peroxide biosynthetic process,GO:0050665,Non-alcoholic Fatty Liver Disease,MESH:D065626,21,"Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Cholesterol, Dietary|Dietary Fats|Ethanol|Folic Acid|Genistein|Glucose|perfluorooctanoic acid|Plant Extracts|Prednisolone|Quercetin|Resveratrol|Silymarin|sodium arsenite|Streptozocin|Tamoxifen|Taurine|tributyltin",1,CYP1A2
hydrogen peroxide catabolic process,GO:0042744,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Copper|sodium arsenite,2,CAT|PRDX3
hydrogen peroxide metabolic process,GO:0042743,Non-alcoholic Fatty Liver Disease,MESH:D065626,12,Acetaminophen|Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Dextran Sulfate|Dietary Fats|Ethanol|Resveratrol|sodium arsenite|Streptozocin|Thioctic Acid,0,
hydrogen sulfide biosynthetic process,GO:0070814,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Caffeine|Glucose,0,
hydrogen sulfide metabolic process,GO:0070813,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|sodium arsenite,0,
hydroperoxide metabolic process,GO:2001290,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,0,
hypermethylation of CpG island,GO:0044027,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium Chloride|Resveratrol|Tetrachlorodibenzodioxin,0,
hypersensitivity,GO:0002524,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tobacco Smoke Pollution,0,
hypomethylation of CpG island,GO:0044029,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Arsenic Trioxide|bisphenol A|sodium arsenite|Tetrachlorodibenzodioxin,0,
hypotonic response,GO:0006971,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Taurine,0,
hypoxanthine biosynthetic process,GO:0046101,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
hypoxanthine metabolic process,GO:0046100,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
icosanoid metabolic process,GO:0006690,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,sodium arsenite|Streptozocin|Tetrachlorodibenzodioxin,0,
I-kappaB kinase/NF-kappaB signaling,GO:0007249,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Plant Extracts|Reactive Oxygen Species|sodium arsenite,1,IKBKG
I-kappaB phosphorylation,GO:0007252,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,"Resveratrol|theaflavin-3,3'-digallate",1,IKBKG
imaginal disc eversion,GO:0007561,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
immune response,GO:0006955,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Dust|Genistein|perfluorooctanoic acid|Quercetin|sodium arsenite|Tobacco Smoke Pollution,15,C1QC|CSF2|FAS|IKBKG|IL1A|IL1B|IL1RN|IL3|IL4|JAK2|LIF|PRF1|TNF|TNFRSF1B|XBP1
immune response-regulating cell surface receptor signaling pathway,GO:0002768,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNFRSF1B
immune response to tumor cell,GO:0002418,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRF1
immune system process,GO:0002376,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,2,AHR|IFI30
immunoglobulin mediated immune response,GO:0016064,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,4-hydroxy-2-nonenal,1,PRKCD
immunoglobulin production,GO:0002377,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Tetrachlorodibenzodioxin|Triclosan,1,FAS
immunoglobulin production involved in immunoglobulin-mediated immune response,GO:0002381,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Coal|perfluorooctanoic acid|Plant Extracts|Tetrachlorodibenzodioxin,0,
immunoglobulin V(D)J recombination,GO:0033152,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RAG2
immunological synapse formation,GO:0001771,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRF1
import across plasma membrane,GO:0098739,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Bile Acids and Salts,0,
import into cell,GO:0098657,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Copper|Glucose|Iron|tributyltin,0,
import into nucleus,GO:0051170,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
indole metabolic process,GO:0042431,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Benzo(a)pyrene|Dextran Sulfate,0,
induction by symbiont of defense-related host reactive oxygen species production,GO:0052064,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,cobaltiprotoporphyrin,0,
induction by virus of host cytokine production,GO:0044832,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"theaflavin-3,3'-digallate",0,
induction of positive chemotaxis,GO:0050930,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRKCA
inflammatory cell apoptotic process,GO:0006925,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
inflammatory response,GO:0006954,Non-alcoholic Fatty Liver Disease,MESH:D065626,47,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Cholesterol|Cholesterol, Dietary|Choline|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Carbohydrates|Dietary Fats|Dietary Sugars|Diethylnitrosamine|Dimethylnitrosamine|Dust|Endotoxins|Ethanol|Fructose|Genistein|hydroquinone|Irinotecan|Iron|Methionine|Oleic Acid|Palm Oil|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Quercetin|Resveratrol|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|tectorigenin|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Tunicamycin|Valproic Acid",14,CD14|FOLR2|GSTP1|IKBKG|IL1A|IL1B|IL1RN|NFE2L2|NLRP3|NR1H4|PPARG|TGFB1|TNF|TNFRSF1B
inflammatory response to antigenic stimulus,GO:0002437,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|perfluorooctanoic acid|Resveratrol,2,IL1B|IL1RN
inflammatory response to wounding,GO:0090594,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TNF
inhibin secretion,GO:0032334,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
inhibitory chemical synaptic transmission,GO:0098977,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
inhibitory postsynaptic potential,GO:0060080,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium Chloride|Orlistat|Sulpiride,0,
initiation of primordial ovarian follicle growth,GO:0001544,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,alpha-naphthoflavone|bisphenol A,0,
innate immune response,GO:0045087,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Endotoxins|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution,7,C1QC|CD14|IKBKG|NLRP3|NQO1|NR1H4|PPARG
innate immune response in mucosa,GO:0002227,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL4
innate vocalization behavior,GO:0098582,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Tetrachlorodibenzodioxin,0,
inner cell mass cell differentiation,GO:0001826,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NR5A2
inner cell mass cell proliferation,GO:0001833,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
inner ear development,GO:0048839,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
innervation,GO:0060384,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
inorganic cation import across plasma membrane,GO:0098659,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Reactive Oxygen Species|Resveratrol,0,
inorganic ion homeostasis,GO:0098771,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Copper,0,
inositol biosynthetic process,GO:0006021,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
inositol metabolic process,GO:0006020,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
inositol phosphate biosynthetic process,GO:0032958,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
inositol phosphate catabolic process,GO:0071545,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
inositol phosphate metabolic process,GO:0043647,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
insecticide metabolic process,GO:0017143,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
instar larval development,GO:0002168,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
insulin-like growth factor receptor signaling pathway,GO:0048009,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Ethanol,0,
insulin metabolic process,GO:1901142,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,bisphenol A|Cadmium|Dietary Fats|gypenoside LXXV|Plant Extracts|Resveratrol|sodium arsenite|Streptozocin|Taurine|Thioctic Acid,0,
insulin processing,GO:0030070,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Streptozocin,0,
insulin receptor internalization,GO:0038016,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
insulin receptor signaling pathway,GO:0008286,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Plant Preparations|puerarin|Streptozocin,3,INS|PDK4|SREBF1
insulin secretion,GO:0030073,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Dietary Fats|Niacinamide,4,IL1RN|LEP|PRKCE|SREBF1
integrated stress response signaling,GO:0140467,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,EIF2AK1|NFE2L2
interleukin-10 production,GO:0032613,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"Acetaminophen|bisphenol A|Fatty Acids, Omega-3",1,PRKCD
interleukin-12-mediated signaling pathway,GO:0035722,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
interleukin-12 production,GO:0032615,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Preparations,1,PRKCD
interleukin-13 production,GO:0032616,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Chromium,0,
interleukin-17 production,GO:0032620,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|bisphenol A,0,
interleukin-18 production,GO:0032621,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NLRP3
interleukin-1 beta production,GO:0032611,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,IL1B|NLRP3
interleukin-1-mediated signaling pathway,GO:0070498,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL1B
interleukin-1 production,GO:0032612,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NLRP3
interleukin-22 production,GO:0032626,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide,0,
interleukin-23-mediated signaling pathway,GO:0038155,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
interleukin-2 production,GO:0032623,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
interleukin-33 production,GO:0072639,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL1A
interleukin-35-mediated signaling pathway,GO:0070757,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
interleukin-3-mediated signaling pathway,GO:0038156,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,IL3|JAK2
interleukin-4-mediated signaling pathway,GO:0035771,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL4
interleukin-5-mediated signaling pathway,GO:0038043,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
interleukin-6-mediated signaling pathway,GO:0070102,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
interleukin-6 production,GO:0032635,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"Acetaminophen|Arsenic Trioxide|Fatty Acids, Omega-3",2,IL1B|TNF
inter-male aggressive behavior,GO:0002121,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Ethanol,0,
intermembrane lipid transfer,GO:0120009,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MTTP
intestinal absorption,GO:0050892,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Dietary Fats,1,LEP
intestinal cholesterol absorption,GO:0030299,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LDLR
intestinal epithelial cell development,GO:0060576,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Choline|Folic Acid,0,
intestinal epithelial cell differentiation,GO:0060575,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|geraniol,0,
intestinal epithelial cell maturation,GO:0060574,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
intestinal epithelial structure maintenance,GO:0060729,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,"Arsenic Trioxide|bisphenol A|Blood Glucose|Dextran Sulfate|Dietary Fats|Ethanol|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Orlistat|Pioglitazone|Thioctic Acid",0,
intestinal lipid absorption,GO:0098856,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SCARB1
intestinal motility,GO:0120054,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Blood Glucose,0,
intestinal stem cell homeostasis,GO:0036335,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,CAT|XBP1
intracellular bile acid receptor signaling pathway,GO:0038185,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,NR1H4
intracellular distribution of mitochondria,GO:0048312,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Valproic Acid,0,
intracellular estrogen receptor signaling pathway,GO:0030520,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Genistein|perfluorohexanesulfonic acid|Raloxifene Hydrochloride|Tamoxifen,2,AHR|ESR1
intracellular pH elevation,GO:0051454,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Sucrose,0,
intracellular pH reduction,GO:0051452,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Arsenic Trioxide|Cadmium|Cadmium Chloride|Glucose,0,
intracellular receptor signaling pathway,GO:0030522,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,6,AHR|AHR2|NR1H4|NR5A2|PPARD|SREBF1
intracellular sequestering of iron ion,GO:0006880,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Acetaminophen,0,
intracellular signal transduction,GO:0035556,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,6,JAK2|LEP|NLRP3|PRKCA|PRKCD|PRKCE
intracellular steroid hormone receptor signaling pathway,GO:0030518,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,ESR1|PPARA|PPARD
intrahepatic bile duct development,GO:0035622,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Taurine,0,
intrinsic apoptotic signaling pathway,GO:0097193,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Extracts,2,PRKCA|SIRT1
intrinsic apoptotic signaling pathway in response to DNA damage,GO:0008630,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,3,SIRT1|TNF|TNFRSF1B
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,GO:0042771,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SIRT1
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,GO:0070059,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|bisphenol A,2,TRIB3|XBP1
intrinsic apoptotic signaling pathway in response to oxidative stress,GO:0008631,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Reactive Oxygen Species,3,ALDH2|JAK2|PRKCD
iodide transport,GO:0015705,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Quercetin,0,
IRE1-mediated unfolded protein response,GO:0036498,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,XBP1
IRES-dependent viral translational initiation,GO:0075522,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
iron import into cell,GO:0033212,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Dietary Fats|Iron|Maneb|Quercetin|Resveratrol,0,
iron ion homeostasis,GO:0055072,Non-alcoholic Fatty Liver Disease,MESH:D065626,16,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|bisphenol A|Cadmium|Cadmium Chloride|Dietary Fats|Ethanol|Folic Acid|Iron|Palmitic Acid|Quercetin|Rosiglitazone|sodium arsenite|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution|Valproic Acid",0,
iron ion import across cell outer membrane,GO:0098706,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Quercetin,0,
iron ion import across plasma membrane,GO:0098711,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Iron,0,
iron ion transport,GO:0006826,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium Chloride|Iron,0,
isoleucine biosynthetic process,GO:0009097,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Dietary Fats|perfluorooctanoic acid,0,
isotype switching to IgE isotypes,GO:0048289,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL4
isotype switching to IgG isotypes,GO:0048291,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL4
JNK cascade,GO:0007254,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Arsenic Trioxide|bisphenol A|Plant Extracts|Reactive Oxygen Species|Resveratrol|sodium arsenite,4,IL1B|IL3|TNF|TRIB1
juvenile hormone mediated signaling pathway,GO:0035626,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,0,
juvenile hormone metabolic process,GO:0006716,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
keratinization,GO:0031424,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Tetrachlorodibenzodioxin|Tobacco Smoke Pollution,1,IL1A
keratinocyte migration,GO:0051546,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PPARD
keratinocyte proliferation,GO:0043616,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,1,PPARD
ketone body biosynthetic process,GO:0046951,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,0,
kidney development,GO:0001822,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,3,ACE|ALDH1A1|CAT
kidney morphogenesis,GO:0060993,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,AHR
killing of cells of another organism,GO:0031640,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRF1
labyrinthine layer development,GO:0060711,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Cadmium Chloride|perfluorohexanesulfonic acid,0,
lactate biosynthetic process,GO:0019249,Non-alcoholic Fatty Liver Disease,MESH:D065626,16,"Acetaminophen|bisphenol A|Cadmium Chloride|Choline|Copper|Dietary Fats|Folic Acid|geraniol|Glucose|Irinotecan|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Resveratrol|sodium arsenite|Streptozocin|Tamoxifen|tributyltin",0,
lactate metabolic process,GO:0006089,Non-alcoholic Fatty Liver Disease,MESH:D065626,19,Acetaminophen|Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|cyanoginosin LR|Dextran Sulfate|Ethanol|Fructose|Genistein|Glucose|perfluorooctanoic acid|puerarin|Quercetin|Resveratrol|Rosiglitazone|sodium arsenite|Streptozocin|Tobacco Smoke Pollution,0,
lactate transport,GO:0015727,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"bisphenol A|Cadmium|Cadmium Chloride|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride",0,
lactation,GO:0007595,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Folic Acid|perfluorooctanoic acid,1,PPARA
lactic acid secretion,GO:0046722,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Acetaminophen|Cadmium|Cadmium Chloride|Dietary Fats,0,
lactone metabolic process,GO:1901334,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
lactose metabolic process,GO:0005988,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
L-alanine catabolic process,GO:0042853,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Acetaminophen|Genistein,1,GPT
"L-alanine catabolic process, by transamination",GO:0019481,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Dimethylnitrosamine|Plant Extracts|puerarin,0,
L-alanine metabolic process,GO:0042851,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,GPT
L-alanine oxidation to D-lactate and ammonia,GO:0019479,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
L-alanine transport,GO:0015808,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
lamellipodium assembly,GO:0030032,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Ethanol,0,
Langerhans cell differentiation,GO:0061520,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
L-arginine import across plasma membrane,GO:0097638,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Sucrose,0,
larval behavior,GO:0030537,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Benzo(a)pyrene|sodium arsenite,0,
larval development,GO:0002164,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|perfluorohexanesulfonic acid|Quercetin|sodium arsenite|Triclosan|Valproic Acid,1,PTEN
larval locomotory behavior,GO:0008345,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Copper|perfluorohexanesulfonic acid|Valproic Acid,0,
larval midgut histolysis,GO:0035069,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
L-ascorbic acid biosynthetic process,GO:0019853,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,Benzo(a)pyrene|Cadmium|Cadmium Chloride|Dietary Fats|Quercetin|Silymarin|Streptozocin|Tamoxifen,0,
L-ascorbic acid metabolic process,GO:0019852,Non-alcoholic Fatty Liver Disease,MESH:D065626,11,Cadmium|Cadmium Chloride|Diethylnitrosamine|Ethanol|Fructose|Iron|Maneb|Palmitic Acid|Resveratrol|sodium arsenite|Streptozocin,0,
L-ascorbic acid transmembrane transport,GO:0015882,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
lateral inhibition,GO:0046331,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SIRT1
lead ion transport,GO:0015692,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Carbohydrates|Dietary Fats,0,
learned vocalization behavior or vocal learning,GO:0098598,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,mancozeb,0,
learning,GO:0007612,Non-alcoholic Fatty Liver Disease,MESH:D065626,14,Acetaminophen|Benzo(a)pyrene|bisphenol A|Dietary Fats|Folic Acid|Fructose|Glucose|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Plant Extracts|Resveratrol|sodium arsenite|Streptozocin|Tetrachlorodibenzodioxin,0,
learning or memory,GO:0007611,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,"Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|theaflavin-3,3'-digallate",3,IL1B|PRKCA|PTEN
left/right pattern formation,GO:0060972,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FTO
lens development in camera-type eye,GO:0002088,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LAMA1
lens fiber cell differentiation,GO:0070306,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
leptin-mediated signaling pathway,GO:0033210,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,LEP|SIRT1
leucine biosynthetic process,GO:0009098,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
leucine catabolic process,GO:0006552,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,geraniol,0,
leucine metabolic process,GO:0006551,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dextran Sulfate|perfluorooctanoic acid,0,
leukemia inhibitory factor signaling pathway,GO:0048861,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LIF
leukocyte activation,GO:0045321,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Benzo(a)pyrene|bisphenol A|Reactive Oxygen Species,0,
leukocyte chemotaxis,GO:0030595,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Acetaminophen|Niacinamide|Prednisolone|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution,0,
leukocyte chemotaxis involved in inflammatory response,GO:0002232,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,Blood Glucose|Dextran Sulfate|Dietary Fats|Diethylnitrosamine|Ethanol|Quercetin|Resveratrol|sodium arsenite,0,
leukocyte degranulation,GO:0043299,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Eucalyptol,0,
leukocyte differentiation,GO:0002521,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dust|Endotoxins,0,
leukocyte homeostasis,GO:0001776,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,Arsenic Trioxide|Cadmium|Dextran Sulfate|Dust|Endotoxins|Plant Extracts|Resveratrol|sodium arsenite|Tobacco Smoke Pollution,0,
leukocyte mediated cytotoxicity,GO:0001909,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRF1
leukocyte migration,GO:0050900,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Benzo(a)pyrene|Dietary Fats|Tobacco Smoke Pollution,2,IL1B|TNF
leukocyte migration involved in immune response,GO:0002522,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Irinotecan|Testosterone,0,
leukocyte migration involved in inflammatory response,GO:0002523,Non-alcoholic Fatty Liver Disease,MESH:D065626,51,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|Allopurinol|aroclor 1260|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Carvedilol|Choline|Coal|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Carbohydrates|Dietary Fats|Diethylnitrosamine|Dimethylnitrosamine|Dust|Ethanol|Fatty Acids, Omega-3|Folic Acid|Fructose|gastrodin|geraniol|hydroquinone|Irinotecan|Iron|Methionine|obeticholic acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Prednisolone|Quercetin|Raloxifene Hydrochloride|Resveratrol|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Tamoxifen|Taurine|Testosterone|Tetrachlorodibenzodioxin|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Valproic Acid",2,NLRP3|TNF
leukocyte proliferation,GO:0070661,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Benzo(a)pyrene|Plant Extracts,1,TGFB1
leukocyte tethering or rolling,GO:0050901,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,2,LEP|TNF
leukotriene B4 biosynthetic process,GO:0097251,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Rosiglitazone|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution,0,
leukotriene biosynthetic process,GO:0019370,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
leukotriene metabolic process,GO:0006691,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tetrachlorodibenzodioxin,0,
leukotriene production involved in inflammatory response,GO:0002540,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Rosiglitazone|Tobacco Smoke Pollution,0,
leukotriene transport,GO:0071716,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ABCC2
Leydig cell differentiation,GO:0033327,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|sodium arsenite|Streptozocin,1,CYP17A1
Leydig cell proliferation,GO:0160024,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,Benzo(a)pyrene|bisphenol A|Cadmium Chloride|Cholesterol|Fructose|Glucose|Sucrose,0,
L-glutamate import,GO:0051938,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Valproic Acid,0,
L-glutamate transmembrane transport,GO:0015813,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
ligand-gated ion channel signaling pathway,GO:1990806,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,F2
limb bud formation,GO:0060174,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Glucose,0,
limb development,GO:0060173,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Ethanol|Folic Acid|Thioctic Acid,0,
linoleic acid metabolic process,GO:0043651,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Linoleic Acid|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid,2,GSTA1|GSTP1
lipid biosynthetic process,GO:0008610,Non-alcoholic Fatty Liver Disease,MESH:D065626,44,"3,4,5,3',4'-pentachlorobiphenyl|Allopurinol|Benzo(a)pyrene|Bezafibrate|bisphenol A|Caffeine|Cholesterol|Cholesterol, Dietary|Choline|cobaltiprotoporphyrin|Dietary Fats|Ethanol|Fatty Acids, Omega-3|Fenofibrate|Fructose|Glucose|Iron|Linoleic Acid|Lipids|Methionine|Niacin|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|obeticholic acid|Oleic Acid|Orlistat|Palmitates|Palmitic Acid|perfluorooctanoic acid|Plant Extracts|Quercetin|Resveratrol|Rosiglitazone|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Sucrose|Tamoxifen|Testosterone|Tetrachlorodibenzodioxin|tributyltin|Triglycerides|Tunicamycin|Valproic Acid",1,SREBF1
lipid catabolic process,GO:0016042,Non-alcoholic Fatty Liver Disease,MESH:D065626,68,"2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine|3,4,5,3',4'-pentachlorobiphenyl|4-hydroxy-2-nonenal|Acetaminophen|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Carvedilol|Cholesterol|Cholesterol, Dietary|Choline|cobaltiprotoporphyrin|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Carbohydrates|Dietary Fats|Dietary Sucrose|Diethylnitrosamine|Dimethylnitrosamine|Ethanol|Fatty Acids, Omega-3|Fenofibrate|Folic Acid|Fructose|gastrodin|Genistein|geraniol|Glucose|hydroquinone|Irinotecan|Iron|Linoleic Acid|mancozeb|Maneb|Methionine|Niacin|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Oleic Acid|Olive Oil|Orlistat|osteum|Palmitic Acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Plant Preparations|Prednisolone|puerarin|Quercetin|Resveratrol|Rosiglitazone|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Sulpiride|Taurine|Testosterone|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Triglycerides|Valproic Acid",1,PNPLA3
lipid droplet disassembly,GO:1905691,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Arsenic Trioxide|Taurine,0,
lipid droplet formation,GO:0140042,Non-alcoholic Fatty Liver Disease,MESH:D065626,68,"3,4,5,3',4'-pentachlorobiphenyl|aroclor 1260|Arsenic Trioxide|Benzo(a)pyrene|Bile Acids and Salts|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Cholesterol, Dietary|Choline|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Fats|Dietary Sucrose|Dietary Sugars|Dust|Ethanol|Fatty Acids, Omega-3|Fenofibrate|flavangenol|Folic Acid|Fructose|Genistein|Glucose|Hydralazine|hydroquinone|Iron|Lipids|Methionine|Niacin|Niacinamide|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|obeticholic acid|Olanzapine|Oleic Acid|Olive Oil|omaveloxolone|Orlistat|Orotic Acid|osteum|Palmitates|Palmitic Acid|perfluorohexanesulfonic acid|perfluorooctanoic acid|Pioglitazone|pirinixic acid|Prednisolone|Quercetin|Raloxifene Hydrochloride|Resveratrol|Rosiglitazone|S-Adenosylmethionine|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Sucrose|Tamoxifen|Taurine|Tetrachlorodibenzodioxin|theaflavin-3,3'-digallate|tributyltin|Triclosan|Triglycerides|Tunicamycin|Valproic Acid",0,
lipid droplet organization,GO:0034389,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|Ethanol|Palmitic Acid|perfluorooctanoic acid|Quercetin|Rosiglitazone,1,PNPLA3
lipid homeostasis,GO:0055088,Non-alcoholic Fatty Liver Disease,MESH:D065626,30,"4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid|Allopurinol|bisphenol A|Butter|Cholesterol|Cholesterol, Dietary|Choline|Dietary Carbohydrates|Dietary Fats|Dietary Sucrose|Ethanol|Fenofibrate|Fructose|geraniol|GW 4064|Lipids|Maneb|Margarine|Methionine|obeticholic acid|perfluorohexanesulfonic acid|perfluorooctanoic acid|Plant Extracts|Quercetin|Resveratrol|Rosiglitazone|Streptozocin|Tobacco Smoke Pollution|tributyltin|Triglycerides",5,ABCB4|PNPLA3|PPARG|PTEN|TM6SF2
lipid hydroxylation,GO:0002933,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP2E1
lipid import into cell,GO:0140354,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,2-acetyltributylcitrate|bisphenol A|Coptidis rhizoma extract|Dietary Fats|Lipids|Rosiglitazone|Tamoxifen|Triglycerides|tuberostemonine,0,
lipid localization,GO:0010876,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Folic Acid|Thioctic Acid,0,
lipid metabolic process,GO:0006629,Non-alcoholic Fatty Liver Disease,MESH:D065626,34,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|bisphenol A|Cadmium|Cadmium Chloride|Cholates|Cholesterol|Cholesterol, Dietary|Choline|Chromium|Copper|Dietary Fats|Ethanol|Fenofibrate|Folic Acid|Glucose|GW 501516|Linoleic Acid|Lipids|Oleic Acid|osteum|Palmitic Acid|perfluorohexanesulfonic acid|perfluoro-n-nonanoic acid|perfluorooctanoic acid|Pioglitazone|Quercetin|Rosiglitazone|sodium arsenite|Tobacco Smoke Pollution|tributyltin|Triclosan|Triglycerides|Valproic Acid",17,ABCB4|ATP5F1B|GSTA1|IL1RN|LDLR|LEP|MTTP|NR1H4|PEMT|PNPLA3|PPARA|PPARD|PPARG|PTEN|SREBF1|TM6SF2|XBP1
lipid oxidation,GO:0034440,Non-alcoholic Fatty Liver Disease,MESH:D065626,73,"4-hydroxy-2-nonenal|5-(3-methoxy-5-(4-methoxystyryl)phenoxy)-2,2-dimethylpentanoic acid|Acetaminophen|Allopurinol|aroclor 1260|Arsenic Trioxide|Benzo(a)pyrene|Bezafibrate|Bile Acids and Salts|bisphenol A|Blood Glucose|Cadmium|Cadmium Chloride|Caffeine|Carvedilol|Cholesterol|Cholesterol, Dietary|Choline|cobaltiprotoporphyrin|Copper|cyanoginosin LR|Dextran Sulfate|Dietary Fats|Dietary Sucrose|Diethylnitrosamine|Dimethylnitrosamine|Dust|Ethanol|Fatty Acids, Omega-3|Fenofibrate|Folic Acid|Fructose|Genistein|geraniol|Glucose|hugan qingzhi|hydroquinone|Irinotecan|Iron|Lipids|mancozeb|Maneb|Methionine|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|obeticholic acid|Oleic Acid|Orlistat|osteum|Palmitic Acid|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Plant Preparations|Prednisolone|puerarin|Quercetin|Reactive Oxygen Species|Resveratrol|Rosiglitazone|S-Adenosylmethionine|Silymarin|sodium arsenite|Sodium Glutamate|Streptozocin|Tamoxifen|Taurine|Testosterone|Thioctic Acid|Tobacco Smoke Pollution|tributyltin|Triclosan|Tunicamycin|Valproic Acid",0,
lipid storage,GO:0019915,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Plant Extracts|Rosiglitazone,0,
lipid transport,GO:0006869,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Diethylnitrosamine,3,MTTP|SCARB1|VLDLR
lipid transport involved in lipid storage,GO:0010877,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Oleic Acid|Palmitic Acid|Tetrachlorodibenzodioxin,0,
lipoate metabolic process,GO:0009106,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Thioctic Acid,0,
lipopolysaccharide biosynthetic process,GO:0009103,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Cadmium Chloride|Dextran Sulfate|Dietary Fats|Streptozocin,0,
lipopolysaccharide-mediated signaling pathway,GO:0031663,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,4,CD14|JAK2|PRKCE|SCARB1
lipopolysaccharide metabolic process,GO:0008653,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Dextran Sulfate|Dietary Fats|obeticholic acid|Orlistat,0,
lipopolysaccharide transport,GO:0015920,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,acanthoic acid|Ethanol|perfluorooctanoic acid,1,SCARB1
lipoprotein biosynthetic process,GO:0042158,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Acetaminophen|bisphenol A|Cadmium|Streptozocin,1,MTTP
lipoprotein catabolic process,GO:0042159,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LDLR
lipoprotein lipid oxidation,GO:0034439,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Copper|Quercetin,0,
lipoprotein metabolic process,GO:0042157,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,"bisphenol A|Cholesterol, Dietary",3,LDLR|MTTP|PPARA
lipoprotein oxidation,GO:0042161,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Quercetin|Resveratrol,0,
lipoprotein transport,GO:0042953,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,MTTP|PPARG
lipoxin A4 biosynthetic process,GO:2001303,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,"3,4,5,3',4'-pentachlorobiphenyl",0,
lipoxin A4 metabolic process,GO:2001302,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium Chloride,0,
liver development,GO:0001889,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"3,4,5,3',4'-pentachlorobiphenyl|Cadmium|Cadmium Chloride|Quercetin",9,AHR|ALDH1A1|ALDH2|ATP5F1B|NR5A2|PNPLA3|SREBF1|TRIB1|XBP1
liver morphogenesis,GO:0072576,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorohexanesulfonic acid,0,
liver regeneration,GO:0097421,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Acetaminophen|geraniol|obeticholic acid|Silymarin,4,CPT1A|FAS|TGFB1|TNF
locomotion,GO:0040011,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Benzo(a)pyrene|bisphenol A|Ethanol|Raloxifene Hydrochloride|Rosiglitazone|Tamoxifen,0,
locomotion involved in locomotory behavior,GO:0031987,Non-alcoholic Fatty Liver Disease,MESH:D065626,27,"Acetaminophen|Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|Cholesterol, Dietary|Chromium|Copper|Dabigatran|Dietary Fats|Ethanol|Glucose|hydroquinone|Olanzapine|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Quercetin|Resveratrol|sodium arsenite|Streptozocin|Sulpiride|Taurine|Triclosan|Valproic Acid",0,
locomotor rhythm,GO:0045475,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
locomotory behavior,GO:0007626,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,"bisphenol A|Dietary Fats|Dietary Sucrose|Ethanol|Fatty Acids, Omega-3|mancozeb|Prednisolone|Resveratrol|Testosterone|Valproic Acid",1,PTEN
locomotory exploration behavior,GO:0035641,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|Cadmium|Ethanol|Folic Acid|sodium arsenite|Streptozocin,1,PRKCE
locus ceruleus development,GO:0021703,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
long-chain fatty acid biosynthetic process,GO:0042759,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,"3,4,5,3',4'-pentachlorobiphenyl|Oleic Acid",2,CYP1A2|CYP2E1
long-chain fatty acid metabolic process,GO:0001676,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Dietary Fats|Linoleic Acid|Oleic Acid|Palmitic Acid|Sodium Glutamate,3,CPT1A|CYP2E1|PNPLA3
long-chain fatty acid transport,GO:0015909,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,MTTP|PPARG
long-term memory,GO:0007616,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,"Ethanol|Glucose|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|sodium arsenite|Streptozocin|Tamoxifen|Testosterone",1,LDLR
long-term synaptic depression,GO:0060292,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,1,PTEN
long-term synaptic potentiation,GO:0060291,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Benzo(a)pyrene|bisphenol A|Ethanol,1,PTEN
low-density lipoprotein particle clearance,GO:0034383,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Tamoxifen,3,ADIPOQ|LDLR|SCARB1
low-density lipoprotein particle remodeling,GO:0034374,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Glucose|Quercetin,1,MTTP
low-density lipoprotein receptor particle metabolic process,GO:0032799,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
L-phenylalanine biosynthetic process,GO:0009094,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Irinotecan|perfluorooctanoic acid|sodium arsenite,0,
L-phenylalanine metabolic process,GO:0006558,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
L-serine biosynthetic process,GO:0006564,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Acetaminophen,0,
L-serine metabolic process,GO:0006563,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Niacin|Resveratrol,0,
L-serine transport,GO:0015825,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
lung alveolus development,GO:0048286,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,3,ACE|LIF|TGFB1
lung development,GO:0030324,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,5,ACE|CYP1A2|LIF|SREBF1|TGFB1
lung growth,GO:0060437,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Cadmium Chloride|Endotoxins,0,
lung lobe morphogenesis,GO:0060463,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LIF
lung vasculature development,GO:0060426,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LIF
luteinization,GO:0001553,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,"3,4,5,3',4'-pentachlorobiphenyl|Arsenic Trioxide|bisphenol A|cyanoginosin LR|perfluorooctanoic acid|Raloxifene Hydrochloride|Streptozocin|Tamoxifen|Tobacco Smoke Pollution|tributyltin",1,MMP1
luteinizing hormone secretion,GO:0032275,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|perfluorooctanoic acid,0,
luteolysis,GO:0001554,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MMP1
lymph gland development,GO:0048542,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
lymph node development,GO:0048535,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
lymphocyte activation,GO:0046649,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Cadmium|Streptozocin|Tamoxifen|Tetrachlorodibenzodioxin,0,
lymphocyte apoptotic process,GO:0070227,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,FAS
lymphocyte chemotaxis,GO:0048247,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Arsenic Trioxide|Dust|sodium arsenite|Tobacco Smoke Pollution,0,
lymphocyte differentiation,GO:0030098,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dust|Endotoxins,1,RAG2
lymphocyte homeostasis,GO:0002260,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,Dextran Sulfate|Diethylnitrosamine|Dust|Endotoxins|Ethanol|Plant Extracts|Quercetin|sodium arsenite,1,AHR
lymphocyte migration,GO:0072676,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Arsenic Trioxide|bisphenol A|Dextran Sulfate|Iron|Quercetin|Tobacco Smoke Pollution,0,
lysine biosynthetic process,GO:0009085,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
lysine metabolic process,GO:0006553,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
lysosomal lumen acidification,GO:0007042,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium|Cadmium Chloride|Copper,0,
lysosomal lumen pH elevation,GO:0035752,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"Cadmium|Cadmium Chloride|theaflavin-3,3'-digallate",0,
lysosomal membrane organization,GO:0097212,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Copper|Quercetin,0,
lysosomal protein catabolic process,GO:1905146,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
lysosome organization,GO:0007040,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,4-hydroxy-2-nonenal|Arsenic Trioxide|Cadmium Chloride|Cholesterol|Copper|Plant Extracts,0,
macroautophagy,GO:0016236,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Niacinamide,0,
macrophage activation,GO:0042116,Non-alcoholic Fatty Liver Disease,MESH:D065626,9,bisphenol A|Cadmium|Cadmium Chloride|cyanoginosin LR|Dextran Sulfate|Irinotecan|Rosiglitazone|sodium arsenite|Valproic Acid,1,IL4
macrophage activation involved in immune response,GO:0002281,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,gypenoside LXXV|Tobacco Smoke Pollution,2,PRKCE|TNF
macrophage chemotaxis,GO:0048246,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dietary Fats,1,IL1B
macrophage cytokine production,GO:0010934,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,2,IL1B|NLRP3
macrophage derived foam cell differentiation,GO:0010742,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Oleic Acid|Palmitic Acid,2,PPARG|TGFB1
macrophage differentiation,GO:0030225,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Tetrachlorodibenzodioxin,4,CSF2|EIF2AK1|LIF|SIRT1
macrophage homeostasis,GO:0061519,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"3,4,5,3',4'-pentachlorobiphenyl|bisphenol A|Tetrachlorodibenzodioxin",0,
macrophage migration,GO:1905517,Non-alcoholic Fatty Liver Disease,MESH:D065626,20,"Acetaminophen|bisphenol A|Cadmium|Cadmium Chloride|Cholesterol, Dietary|Choline|cyanoginosin LR|Dextran Sulfate|Dietary Fats|Dietary Sucrose|Fructose|Glucose|hydroquinone|Methionine|Resveratrol|Rosiglitazone|sodium arsenite|Sodium Glutamate|Streptozocin|Tobacco Smoke Pollution",0,
macrophage proliferation,GO:0061517,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Dextran Sulfate,0,
magnesium ion homeostasis,GO:0010960,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
magnesium ion transmembrane transport,GO:1903830,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Streptozocin,0,
maintenance of blood-brain barrier,GO:0035633,Non-alcoholic Fatty Liver Disease,MESH:D065626,7,"Blood Glucose|Ethanol|Glucose|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Resveratrol|sodium arsenite|tributyltin",0,
maintenance of cell number,GO:0098727,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Plant Extracts|Silymarin|Streptozocin",0,
maintenance of lens transparency,GO:0036438,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH1A1
maintenance of location in cell,GO:0051651,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Palmitic Acid,0,
maintenance of nucleus location,GO:0051658,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,SIRT1
maintenance of protein localization in organelle,GO:0072595,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium Chloride,0,
maintenance of protein location in mitochondrion,GO:0072656,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"geraniol|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|Silymarin",0,
maintenance of protein location in plasma membrane,GO:0072660,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Glucose|sodium arsenite,0,
maintenance of synapse structure,GO:0099558,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Dietary Fats|Dietary Sucrose|Maneb,0,
malate metabolic process,GO:0006108,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
male courtship behavior,GO:0008049,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
"male courtship behavior, orientation prior to leg tapping and wing vibration",GO:0016543,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
"male courtship behavior, proboscis-mediated licking",GO:0016546,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
"male courtship behavior, tapping to detect pheromone",GO:0016544,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
"male courtship behavior, veined wing vibration",GO:0016545,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
male gamete generation,GO:0048232,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Quercetin,0,
male germ cell proliferation,GO:0002176,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
male germ-line stem cell population maintenance,GO:0036098,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|GW 4064|Testosterone,0,
male gonad development,GO:0008584,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,bisphenol A|Cadmium|Cadmium Chloride|Dietary Fats|Pioglitazone|Resveratrol|sodium arsenite|Streptozocin|Tamoxifen|Tetrachlorodibenzodioxin,3,ACE|CYP17A1|ESR1
male mating behavior,GO:0060179,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|sodium arsenite|Tetrachlorodibenzodioxin,1,PTEN
male meiosis I,GO:0007141,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
male meiotic nuclear division,GO:0007140,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
male sex determination,GO:0030238,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,CYP17A1
malonyl-CoA biosynthetic process,GO:2001295,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,cobaltiprotoporphyrin|Streptozocin,0,
mammary duct terminal end bud growth,GO:0060763,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,bisphenol A|Butter|Genistein|Resveratrol|Tetrachlorodibenzodioxin,1,AHR
mammary gland alveolus development,GO:0060749,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,1,ESR1
mammary gland branching involved in pregnancy,GO:0060745,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ESR1
mammary gland branching involved in thelarche,GO:0060744,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
mammary gland bud formation,GO:0060615,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,0,
mammary gland development,GO:0030879,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Olanzapine|perfluorooctanoic acid,1,TGFB1
mammary gland duct morphogenesis,GO:0060603,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
mammary gland epithelium development,GO:0061180,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
mammary gland morphogenesis,GO:0060443,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|perfluoro-n-nonanoic acid,0,
mammary stem cell proliferation,GO:0002174,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
manganese ion homeostasis,GO:0055071,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,"3,4,5,3',4'-pentachlorobiphenyl|Cadmium|Cadmium Chloride|Ethanol|mancozeb",0,
manganese ion transmembrane transport,GO:0071421,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,alpha-naphthoflavone|Iron,0,
manganese ion transport,GO:0006828,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
mannosylation,GO:0097502,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Cadmium|Copper|sodium arsenite|Tunicamycin,0,
MAPK cascade,GO:0000165,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,cyanoginosin LR|Genistein|Glucose|Pioglitazone|Plant Extracts|Raloxifene Hydrochloride|Reactive Oxygen Species|Rosiglitazone|Streptozocin|Tamoxifen,1,PRKCE
mast cell apoptotic process,GO:0033024,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL3
mast cell degranulation,GO:0043303,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Dietary Fats|hydroquinone|perfluorooctanoic acid|Quercetin|Streptozocin,0,
mast cell homeostasis,GO:0033023,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Benzo(a)pyrene|Cadmium|Cadmium Chloride|perfluorooctanoic acid,0,
mast cell migration,GO:0097531,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Quercetin,0,
mast cell proliferation,GO:0070662,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,tributyltin,1,IL3
maternal behavior,GO:0042711,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Acetaminophen,1,PTEN
maternal placenta development,GO:0001893,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Tunicamycin|Valproic Acid,1,PRDX3
maternal process involved in female pregnancy,GO:0060135,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Genistein|Valproic Acid,2,FAS|LIF
maternal process involved in parturition,GO:0060137,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
mating,GO:0007618,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
mating behavior,GO:0007617,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Streptozocin,0,
matrix metallopeptidase secretion,GO:1990773,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cholesterol,0,
mature B cell differentiation involved in immune response,GO:0002313,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RAG2
mature conventional dendritic cell differentiation,GO:0097029,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Plant Extracts,0,
medium-chain fatty acid transport,GO:0001579,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,MTTP
megakaryocyte development,GO:0035855,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Cadmium|Cadmium Chloride,0,
megakaryocyte differentiation,GO:0030219,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
meiosis I cell cycle process,GO:0061982,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Resveratrol,0,
meiotic anaphase I,GO:0007133,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
meiotic cell cycle,GO:0051321,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Cadmium,0,
meiotic cell cycle checkpoint signaling,GO:0033313,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
meiotic cell cycle process,GO:1903046,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
meiotic cell cycle process involved in oocyte maturation,GO:1903537,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,bisphenol A|Cadmium|Cadmium Chloride|Cholesterol,0,
meiotic chromosome separation,GO:0051307,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Tetrachlorodibenzodioxin,0,
meiotic DNA double-strand break formation,GO:0042138,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
meiotic DNA repair synthesis,GO:0000711,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
meiotic metaphase II,GO:0007137,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
meiotic metaphase II plate congression,GO:0043061,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
meiotic nuclear division,GO:0140013,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,LIF
meiotic prophase I,GO:0007128,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
meiotic recombination checkpoint signaling,GO:0051598,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
meiotic telophase I,GO:0007134,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
melanin biosynthetic process,GO:0042438,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,Copper|hydroquinone|Plant Extracts|Quercetin|Resveratrol|sodium arsenite,0,
melanin metabolic process,GO:0006582,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Benzo(a)pyrene|hydroquinone,0,
melanosome localization,GO:0032400,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
melanotic encapsulation of foreign target,GO:0035011,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PTEN
melatonin biosynthetic process,GO:0030187,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
melatonin metabolic process,GO:0030186,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
membrane depolarization,GO:0051899,Non-alcoholic Fatty Liver Disease,MESH:D065626,10,bisphenol A|Cadmium|Cadmium Chloride|Glucose|hydroquinone|Oleic Acid|perfluorooctanoic acid|puerarin|sodium arsenite|Streptozocin,0,
membrane hyperpolarization,GO:0060081,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,bisphenol A|Resveratrol,0,
membrane lipid catabolic process,GO:0046466,Non-alcoholic Fatty Liver Disease,MESH:D065626,46,"3,4,5,3',4'-pentachlorobiphenyl|4-hydroxy-2-nonenal|Acetaminophen|Allopurinol|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Carvedilol|Cholesterol|Choline|Copper|Dietary Carbohydrates|Dietary Fats|Diethylnitrosamine|Dimethylnitrosamine|Ethanol|Fructose|Glucose|Iron|Linoleic Acid|Methionine|Niacin|Olanzapine|perfluorooctanoic acid|Pioglitazone|Plant Extracts|Plant Preparations|Quercetin|Reactive Oxygen Species|Resveratrol|Rosiglitazone|S-Adenosylmethionine|Silymarin|sodium arsenite|Streptozocin|Sucrose|Tamoxifen|Taurine|Testosterone|Tetrachlorodibenzodioxin|theaflavin-3,3'-digallate|Thioctic Acid|Tobacco Smoke Pollution|Toremifene|Valproic Acid",0,
membrane organization,GO:0061024,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|Benzo(a)pyrene|Choline|Quercetin,0,
membrane protein intracellular domain proteolysis,GO:0031293,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,TGFB1
membrane raft organization,GO:0031579,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Triglycerides,0,
membrane repolarization during cardiac muscle cell action potential,GO:0086013,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Arsenic Trioxide,0,
membrane tubulation,GO:0097749,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Folic Acid,0,
memory,GO:0007613,Non-alcoholic Fatty Liver Disease,MESH:D065626,22,Arsenic Trioxide|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Copper|Dietary Fats|Ethanol|Eucalyptol|Folic Acid|Fructose|Linoleic Acid|Maneb|Plant Extracts|Quercetin|Resveratrol|sodium arsenite|Streptozocin|Tamoxifen|Taurine|Tobacco Smoke Pollution|tributyltin,4,IL1B|IL1RN|PTEN|VLDLR
menarche,GO:0042696,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Cadmium,0,
menopause,GO:0042697,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,perfluorooctanoic acid|Tobacco Smoke Pollution,0,
menstrual cycle,GO:0044850,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,mancozeb|Maneb,0,
mercury ion transport,GO:0015694,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ABCC2
mesoderm development,GO:0007498,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
mesoderm formation,GO:0001707,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,PRKACA
metabolic process,GO:0008152,Non-alcoholic Fatty Liver Disease,MESH:D065626,20,Benzo(a)pyrene|bisphenol A|Cholesterol|Choline|Dextran Sulfate|Dietary Fats|Glucose|Linoleic Acid|Niacinamide|Oleic Acid|perfluorohexanesulfonic acid|perfluorooctanoic acid|Plant Extracts|Quercetin|Resveratrol|S-Adenosylmethionine|sodium arsenite|Taurine|Tobacco Smoke Pollution|Triclosan,0,
metal ion homeostasis,GO:0055065,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,Cadmium|Chromium|Copper|Dietary Fats|Iron|sodium arsenite|Tobacco Smoke Pollution|tributyltin,0,
metal ion transport,GO:0030001,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Cadmium|Dietary Carbohydrates|Dietary Fats|tributyltin,0,
metamorphosis,GO:0007552,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,1,PTEN
metestrus,GO:0060210,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,bisphenol A|Genistein|tributyltin,0,
methane metabolic process,GO:0015947,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,sodium arsenite,0,
methionine biosynthetic process,GO:0009086,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Arsenic Trioxide|sodium arsenite|Tamoxifen,0,
methionine metabolic process,GO:0006555,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Methionine|Resveratrol|S-Adenosylmethionine,1,GNMT
methotrexate transport,GO:0051958,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Folic Acid|Resveratrol,0,
methylation,GO:0032259,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Folic Acid|sodium arsenite,3,CYP1A2|GNMT|PEMT
MHC class II biosynthetic process,GO:0045342,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,IL4
microglia development,GO:0014005,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,sodium arsenite|tributyltin,0,
microglial cell activation,GO:0001774,Non-alcoholic Fatty Liver Disease,MESH:D065626,8,Copper|Ethanol|Maneb|Quercetin|Reactive Oxygen Species|Resveratrol|sodium arsenite|Taurine,3,IL4|JAK2|TNF
microglial cell proliferation,GO:0061518,Non-alcoholic Fatty Liver Disease,MESH:D065626,6,bisphenol A|Ethanol|Quercetin|sodium arsenite|Streptozocin|Valproic Acid,0,
micronucleus organization,GO:0032125,Non-alcoholic Fatty Liver Disease,MESH:D065626,17,"3,4,5,3',4'-pentachlorobiphenyl|Benzo(a)pyrene|bisphenol A|Cadmium|Cadmium Chloride|Caffeine|cyanoginosin LR|Diethylnitrosamine|Dimethylnitrosamine|Ethanol|Fatty Acids, Omega-3|Folic Acid|hydroquinone|Methionine|Plant Extracts|Quercetin|sodium arsenite",0,
microtubule anchoring at centrosome,GO:0034454,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,bisphenol A,0,
microtubule cytoskeleton organization,GO:0000226,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,cyanoginosin LR|Reactive Oxygen Species|tributyltin|Valproic Acid,0,
microtubule depolymerization,GO:0007019,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,cyanoginosin LR|Quercetin,0,
microtubule polymerization,GO:0046785,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cadmium Chloride|Quercetin|Resveratrol,0,
microvillus assembly,GO:0030033,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,RDX
microvillus organization,GO:0032528,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"Arsenic Trioxide|Streptozocin|theaflavin-3,3'-digallate",0,
micturition,GO:0060073,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Dietary Fats|Streptozocin,0,
midbrain development,GO:0030901,Non-alcoholic Fatty Liver Disease,MESH:D065626,2,Ethanol|Folic Acid,0,
midgut development,GO:0007494,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,ALDH1A1
mineralocorticoid receptor signaling pathway,GO:0031959,Non-alcoholic Fatty Liver Disease,MESH:D065626,0,,1,JAK2
miRNA transport,GO:1990428,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,perfluorooctanoic acid,0,
mitochondrial ATP synthesis coupled electron transport,GO:0042775,Non-alcoholic Fatty Liver Disease,MESH:D065626,5,Acetaminophen|bisphenol A|Cadmium|Glucose|Pioglitazone,0,
mitochondrial calcium ion homeostasis,GO:0051560,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Arsenic Trioxide|Ethanol|Methionine|sodium arsenite,0,
mitochondrial cytochrome c oxidase assembly,GO:0033617,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,Cholesterol|Copper|Glucose,0,
mitochondrial depolarization,GO:0051882,Non-alcoholic Fatty Liver Disease,MESH:D065626,24,2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide|Acetaminophen|Arsenic Trioxide|bisphenol A|Cadmium|Cadmium Chloride|Chromium|Copper|Dietary Fats|Ethanol|Fructose|Glucose|hydroquinone|Iron|Niacin|obeticholic acid|osteum|Palmitic Acid|puerarin|Resveratrol|sodium arsenite|Streptozocin|Tamoxifen|Taurine,0,
mitochondrial DNA catabolic process,GO:0032043,Non-alcoholic Fatty Liver Disease,MESH:D065626,3,"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|puerarin|Taurine",0,
mitochondrial DNA metabolic process,GO:0032042,Non-alcoholic Fatty Liver Disease,MESH:D065626,4,Dietary Fats|Dust|Folic Acid|Palmitic Acid,0,
mitochondrial DNA repair,GO:0043504,Non-alcoholic Fatty Liver Disease,MESH:D065626,1,Thioctic Acid,0,
mitochondrial DNA replication,GO:0006264,Non-alcoholic Fatty Liver Disease,MESH:D065626,16,"3,4,5,3',4'-pentachlorobiphenyl|Acetaminophen|Benzo(a)pyrene|bisphenol A|Cadmium|Dietary Fats|Glucose|N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride|osteum|Palmitic Acid|Quercetin|Resveratrol|Rosiglitazone|sodium arsenite|Tetrachlorodibenzodioxin|Tobacco Smoke Pollution",0,
"mitochondrial electron transport, cytochrome c to oxygen",GO:0006123,Non-alcoholic Fatty Liver Disease,MESH:D065626,14,Benzo(a)pyrene|bisphenol A|Choline|Copper|Dietary Sucrose|Fenofibrate|Fructose|geraniol|Methionine|Palmitic Acid|Resveratrol|Rosiglitazone|sodium arsenite|Tetrachlorodibenzodioxin,0,
